Nirmatrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 1Title Page
AN INTERVENTIONAL, E FFICACY AND SAFETY, PHASE 2, RANDOMIZED,
DOUBLE -BLIND, 2- ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE 
OF NIRMATRELVIR/RITO NAVIR COMPARED TO PLACEBO/RITONAVIR IN
PARTICIPANTS AT LEAS T 12 YEARS OF AGE WI TH REBOUND OF COVID -19 
SYMPTOMS AND RAPID A NTIGEN TEST POSITIVI TY
Study Intervention Number: PF-07321332
Study Intervention Name: nirmatrelvir
US IND Number: 153517
EudraCT/EU CT Number: 2022- 002827- 36
ClinicalTrials.gov ID:  [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: not available
Protocol Number: C4671042
Phase: 2
Sponsor Legal Address: Pfizer I nc.
66 Hudson Boulevard East
New York, NY 10001
Brief Title:
A Study  to Learn About a Repeat 5- Day Treatment with Nirmatrelvir/Ritonavir in 
People with Return of COVID -19 Symptoms and SARS -CoV -2 Positivity  After 
Finishing Treatment with Nirmatrelvir/Ritonavir
This document and accompanying materials contain confidential information belonging to Pfizer. Except 
as otherwise agreed to in w riting, by accepting or reviewing these documents, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law ) 
or use it for unauth orized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.

Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 2Document History
Document Version Date
Amendment 4 29 June 2023
Amendment 3 12 May  2023
Amendment 2 01 February  2023
Amendment 1 16 September 2022
Original protocol 05 August 2022
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs and any  protocol administrative change 
letter(s).
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 3Protocol Amendment Summary of Changes Table
Amendment 4 ( 29 June 2023)
Overall Rationale for the Amendment: The protocol was primarily amended to add secondary analyse s for the primary and 
secondary efficacy endpoints using the new analysis set (mITT1). Additional revisions are noted in the table below.
Description of Change Brief Rationale Section # and Name
Substantial Modification(s)
Additional secondary analys es for 
primary and secondary efficacy endpoints 
using the new analysis set (mITT1).  
Update the multiplicity adjustment 
accordingly.Based on regulatory feedback on the definition of the study analysis 
set.Section 9.1.2 Multiplicity Adjustment
Section 9.2 Analysis Sets
Section 9.3.2.2 Main Analytical Approach
Section 9.3.3.1 Time to 2 consecutive negative rapid 
antigen test results obt ained at least 24( -2)h apart 
through Day 28
Section 9.3.3.2 Time (days) to sustained alleviation of 
all targeted signs and symptoms through Day 28
Non-substantial Modification(s)
Minor editorial updates. To correct grammatical and formatting errors, and to maintain 
consistency.Throughout the protocol
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 4TABLE OF CONTENTS
LIST OF TABLES ...................................................................................................................10
1. PROTOCOL  SUMMARY ...................................................................................................11
1.1. Sy nopsis ..................................................................................................................11
1.2. Schema ....................................................................................................................18
1.3. Schedule of Activities .............................................................................................19
2. INTRODUCTION ...............................................................................................................31
2.1. Study  Rationale .......................................................................................................31
2.2. Bac kground .............................................................................................................32
2.2.1. Clinical Overview .......................................................................................32
2.3. Benefit/Risk Assessment
.........................................................................................33
2.3.1. Risk Assessment
.........................................................................................34
2.3.2. Benefit Assessment .....................................................................................36
2.3.3. Overall Benefit/Risk Conclusion ................................ ................................ 36
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................36
4. STUDY DESIGN .................................................................................................................39
4.1. Overall Design .........................................................................................................39
4.2. Scientific Rationale for Study  Design .....................................................................40
4.2.1. Choice of Contraception/Barrier Requirements .........................................41
4.2.2. Collection of Retained Research Samples ..................................................41
4.2.3. I nclusion of Pediatric Participants
..............................................................41
4.3. Justification for Dose ..............................................................................................41
4.4. End of Study  Definition ..........................................................................................41
5. STUDY POPUL ATION
......................................................................................................42
5.1. I nclusion Criteria .....................................................................................................42
5.2. Exclusion Criteria ....................................................................................................43
5.3. L ifesty le Considerations ..........................................................................................44
5.3.1. Contraception ..............................................................................................44
5.4. Screen Failures ........................................................................................................45
5.5. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ........................... 45
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY ................................ .45
6.1. Study  Intervention(s) Administered ........................................................................45
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 56.1.1. Administration ............................................................................................47
6.2. Preparation, Handling, Storage, and Accountability ...............................................48
6.2.1. Preparation and Dispensing ........................................................................49
6.3. Assignment to Study I ntervention ...........................................................................49
6.4. Blinding
...................................................................................................................49
6.4.1. Blinding of Participants ..............................................................................49
6.4.2. Blinding of Site Personnel ..........................................................................49
6.4.3. Blinding of the Sponsor
..............................................................................50
6.4.4. Breaking the Blind ......................................................................................50
6.5. Study  Intervention Compliance ...............................................................................50
6.6. Dose Modification ...................................................................................................51
6.7. Continued Access to Study  Intervention After the End of the Study ......................51
6.8. Treatment of Overdose
............................................................................................51
6.9. Prior and Concomitant Therap y ..............................................................................52
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................53
7.1. Discontinuation of Study  Intervention ....................................................................53
7.1.1. Pregnancy ...................................................................................................54
7.2. Participant Discontinuation/Withdrawal From the Study .......................................54
7.2.1. Withdrawal of Consent ...............................................................................54
7.3. L ost to Follow -Up...................................................................................................55
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................55
8.1. Administrative and Baseline Procedures .................................................................55
8.1.1. Baseline Procedures ....................................................................................56
8.1.1.1. Medical History ................................ ................................ ......... 56
8.1.1.2. Secondary  Contacts ...................................................................56
8.1.2. Household Characteristics ..........................................................................57
8.1.3. Telehealth Visits .........................................................................................57
8.1.4. Home Health Visits .....................................................................................57
8.2. Efficacy  Assessments ..............................................................................................58
8.2.1. Participant Diary .........................................................................................58
8.2.2. COVID -
19-Related Medical Details ................................ .......................... 59
8.2.3. PRO Assessments .......................................................................................59
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 68.2.3.1. Global I mpression Questions ....................................................59
8.2.3.2. SF -
36 v2®Health Survey  (Acute Form)[18] .............................59
8.2.3.3. WPAI .........................................................................................59
8.2.3.4. EQ -
5D-5L Scale ........................................................................60
8.2.3.5. COVID -19 Signs and Sy mptoms ..............................................60
8.3. Safet y Assessments .................................................................................................61
8.3.1. Targeted Ph ysical Examination, Height and Weight ..................................61
8.3.2. Vital Signs ..................................................................................................61
8.3.2.1. Blood Pressure and Pulse Rate ..................................................61
8.3.2.2. Temperature and Respiratory  Rate ............................................62
8.3.2.3. Ox ygen Saturation L evel...........................................................62
8.3.2.4. Point -
of-Care Serum Creatinine Assessments ..........................62
8.3.3. Clinical Safety  Laboratory  Assessments ....................................................62
8.3.3.1. Alternative Facilities for Clinical Safety  Laboratory  
Assessment ........................................................................................62
8.3.4. Pregnancy  Testing ......................................................................................63
8.3.4.1. At Home Pregnan cy Testing .....................................................63
8.4. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................63
8.4.1. Time Period and Frequency  for Collecting AE and SAE Information .......64
8.4.1.1. Reporting SAEs to Pfizer Safety ...............................................64
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF
...................64
8.4.2. Method of Detecting AEs and SAEs ..........................................................65
8.4.3. Follow -Up of AEs and SAEs ......................................................................65
8.4.4. Regulatory
 Reporting Requirements for SAEs ...........................................65
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................66
8.4.5.1. Exposure During Pregnancy ................................ ...................... 66
8.4.5.2. Exposure During Breastfeeding ................................................67
8.4.5.3. Occupational Exposure .............................................................68
8.4.6. Cardiovascular and Death Events ................................ ............................... 68
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify ing as AEs or SAEs ..............................................................................68
8.4.8. Adverse Events of Special Interest
.............................................................68
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 78.4.8.1. Lack of Efficacy ........................................................................68
8.4.9. Medical Device Deficiencies ................................ ................................ ......68
8.4.10. Medication Errors .....................................................................................68
8.5. Pharmacokinetics ....................................................................................................69
8.6. Genetics ...................................................................................................................70
8.6.1. Specifi
ed Genetics ......................................................................................70
8.6.2. Retained Research Samples for Genetics
...................................................70
8.7. Biomarkers ..............................................................................................................70
8.7.1. Viral RNA Assessment (NP Swab)
............................................................70
8.7.2. Viral RNA Assessment (Plasma)
................................................................71
8.7.3. Rapid Antigen Assessments .......................................................................71
8.7.4. Viral Sequencing Assessments (OP Swab) ................................................71
8.7.5. Specified Gene Expression (RNA) Research .............................................71
8.7.6. Specified Protein Research .........................................................................71
8.7.6.1. Plasma for Protein Analy sis......................................................71
8.7.7. Specified Metabolomic Research ...............................................................72
8.7.8. Retained Research Samples for Biomarkers ...............................................72
8.8. I mmunogenicit y Assessments .................................................................................72
8.9. Health Economics ...................................................................................................72
9. STATI STICAL CONSI DERATIONS
................................................................................72
9.1. Statistical Hy pothesis ..............................................................................................72
9.1.1. Estimands ....................................................................................................73
9.1.1.1. Primary  Estimand ......................................................................73
9.1.1.2. Secondary  Estimands ................................................................73
9.1.2. Multiplicity  Adjustment ................................ ................................ .............. 73
9.2. Analy sis Sets ...........................................................................................................74
9.3. Statistical Analy ses.................................................................................................74
9.3.1. General Considerations ...............................................................................74
9.3.2. Primary  Endpoint(s)/Estimand(s) Anal ysis................................................75
9.3.2.1. Definition of Endpoint(s)
..........................................................75
9.3.2.2. Main Anal ytical Approach ........................................................75
9.3.3. Secondary  Endpoints ..................................................................................75
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 89.3.3.1. Time to 2 consecutive negative rapid antigen test results 
obtained at least 24( -2)h apart through Day  28 .................................75
9.3.3.2. Time (day s) to sustained alleviation of all targeted signs 
and sy mptoms through Day 28
..........................................................76
9.3.4. Tertiary /Exploratory  Endpoint(s) Anal ysis................................................77
9.3.5. Safet y Anal yses..........................................................................................77
9.3.6. Other Anal yses............................................................................................77
9.4. I nterim Anal yses.....................................................................................................77
9.5. Sample Size Determination .....................................................................................77
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................79
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............79
10.1.1. Regulatory and Ethical Considerations ....................................................79
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................79
10.1.2. Financial Disclosure .................................................................................80
10.1.3. I nformed Consent/Assent Process ............................................................80
10.1.3.1. I nformed Consent Process .......................................................80
10.1.3.2. I nformed Assent Process .........................................................81
10.1.4. Data Protection .........................................................................................82
10.1.5. Committees Structure ...............................................................................83
10.1.5.1. Data Monitoring Committee ...................................................83
10.1.6. Dissemination of Clinical Study  Data ......................................................83
10.1.7. Data Qualit y Assurance ............................................................................84
10.1.8. Source Documents ....................................................................................85
10.1.9. Study  and Site Start and Closure ..............................................................86
10.1.10. Publication Policy ................................ ................................ ................... 86
10.1.11. Sponsor’s Medically  Qualified Individual ..............................................87
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................88
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................89
10.3.1. Definition of AE .......................................................................................89
10.3.2. Definition of an SAE ................................................................................90
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 910.3.3. Recording/Reporting and Follow- Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................91
10.3.4. Reporting of SAEs
....................................................................................95
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................96
10.4.1. Female Participant Reproductive Inclusion Criteria .................................96
10.4.2. Woman of Childbearing Potential ............................................................96
10.4.3. Contraception Methods .............................................................................97
10.5. Appendix 5: Genetics
............................................................................................99
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments 
and Study  Intervention Rechallenge Guidelines
.....................................................100
10.7. Appendix 7: Age -Specific Kidney  Function Calculation Recommendations .....102
10.7.1. Adults (18 Years and Above) —2021 CKD -EPI Equations ................... 102
10.7.1.1. Adolescents (12 Years to <18 Years)—Cockcroft -Gault 
Formula ............................................................................................102
10.7.2. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities .................................................................................................102
10.8. Appendix 8: Prohibited and Precautionary  Concomitant Medications That 
May Result in DDI ..................................................................................................103
10.9. Appendix 9: Country -Specific Requirements .....................................................115
10.9.1. France .....................................................................................................115
10.9.2. German y
.................................................................................................115
10.10. Appendix 10: Eligibility  Criteria
.......................................................................116
10.10.1. Age and S ex..........................................................................................116
10.10.2. Rebound of COVID -19 Signs/S ymptoms ............................................116
10.10.3. SARS -CoV -2 Infection .........................................................................116
10.10.4. Risk of Developing Severe Illness from COVID
-19............................116
10.10.5. Prior/Concomitant Therap y
................................ ................................ ..117
10.10.6. Other Treatments for COVID -19..........................................................118
10.10.7. I mmunocompromised Criteria Details ................................ ................. 118
10.11. Appendix 11: Participant -Reported COVID -19-Related Signs and 
Symptoms ................................................................................................................119
10.12.
Appendix 12: Protocol Ame ndment History .....................................................120
10.13. Appendix 13: Abbreviations .............................................................................125
11. REFERENCES ................................................................................................................128
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 10LIST OF TABLES
Table 1. Study  Schedule of Assessment .................................................................19
Table 2. Protocol -Required Safet y Laboratory  Assessments .................................88
Table 3. Drugs That are Contraindicated With Nirmatrelvir/Ritonavir ................103
Table 4. Established and Other Potentially  Significant Drug I nteractions ...........106
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 111.PROTOCOL SUMMARY 
1.1.Synopsis 
Protocol Title: 
An Interventional, Efficacy  and Safet y, Phase 2, Randomized, Double -Blind, 2 -Arm Study  to 
Investigate a Repeat 5 -Day Course of Nirmatrelvir /Ritonavir Compared to Placebo/Ritonavir 
in Participants at Least 12 Years of Age with Rebound of COVID-19 S ymptoms and Rapid 
Antigen Test Positivity
Brief Title: 
A Study  to Learn About a Repeat 5- Day Treatment with Nirmatrelvir/Ritonavir in People 
with R eturn of COVID -19 Sy mptoms and SARS -CoV -2 Positivity  After Finishing Treatment 
with Nirmatrelvir/Ritonavir
Regulatory Agency Identification Number(s):
US IND Number: 153517
EudraCT/EU CT Number: 2022 -002827 -36
ClinicalTrials.gov ID:  [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: not available
Protocol Number: C4671042
Phase: 2
Rationale:
Case reports in the literature describe individuals who have experienced s ymptomatic 
relapses of SARS -CoV -2 infection following completion of a 5 -day course of 
nirmatrelvir/ritonavir. In the available cases, patients are described as experiencing rapid 
improvement in sy stemic sy mptoms following initiation of treatment but then experience a 
rebound in COVID -19 s ymptoms after completing therap y. The time course of sy mptom 
rebound suggests that s ymptom recurrence is likely  not related to re-exposure and it does not 
reflect a potential re -infection event. In one case report, sy mptom relapse was accompanied 
by fluctuating RT- PCR cy cle thresholds and antigen t esting suggesting the potential for a 
rebound in viral replication. In a separate case series of 7 patients with recurrent s ymptoms, 
median SARS -CoV -2 RNA at baseline was 6.1 log 10copies/mL  (range 4.2- 7.3) and 
enrollment viral cultures were positive in 3 of 7 individuals. Several of the published case 
reports on s ymptom recurrence included viral sequencing and these reports to date have not 
identified resistance mutations to nirmatrelvir.
A retrospective review of 483 high -risk patients treated with nirmat relvir/ritonavir reported 
4 (0.8%) patients who experienced rebound of s ymptoms. Median time to rebound in this 
study  was 9 day s and rebound sy mptoms were characterized as mild and resolving without 
additional COVID -19 therapy  with no patient requiring hos pitalization.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 12Post-treatment increases in SARS -CoV -2 RNA levels (ie, viral RNA rebound) in 
nasophary ngeal samples were observed on Day  10 or Day  14 in a subset of 
nirmatrelvir/ritonavir and placebo recipients in the EPI C-HR study . The frequency  of 
detectio n of post -treatment viral RNA rebound varied according to anal ysis parameters but 
was generall y similar among nirmatrelvir/ritonavir and placebo recipients, regardless of the 
rebound definition used. A similar or smaller percentage of placebo recipients co mpared to 
nirmatrelvir/ritonavir recipients had nasopharyngeal viral RNA results <LLOQ at all study  
timepoints in both the treatment and post -treatment periods. Post -treatment viral RNA 
rebound was not associated with the primary  clinical outcome of COVID -19-related 
hospitalization or death from any  cause through Day  28 following the single 5 -day course of 
nirmatrelvir/ritonavir treatment. Post- treatment viral RNA rebound also was not associated 
with drug resistance as measured b y mPro sequencing. The clinical relevance of 
post-treatment increases in viral RNA following nirmatrelvir/ritonavir or placebo treatment is 
unknown.
At present, there are no controlled efficacy  and safety  data of a repeat 5 -day course of 
nirmatrelvir/ritonavir in participants with ac ute rebound in sy mptoms and SARS -CoV -2 
infection. Recurrence in sy mptoms along with a positive rapid antigen test following the 
completion of a 5 -day course of nirmatrelvir/ritonavir may  indicate that these patients may  
require additional therapy to achiev e sustained viral clearance. Such patients may  benefit 
from an additional 5 -day treatment duration. The purpose of this study  is to evaluate the 
efficacy , safet y and tolerability of a second 5 -day treatment course of nirmatrelvir/ritonavir 
in participants with a rebound in COVI D-19 s ymptoms and a positive rapid antigen test 
within 2 weeks (14 day s) following completion of an initial 5 -day treatment course.
Objectives, Endpoints, and Estimands:
Objectives Endpoints Estimands
Primary: Primary: Primary: 
Tocompare the effect of 
nirmatrelvir/ritonavir to 
placebo /ritonavir on viral RNA level 
in NP swabs in participants with mild -
to-moderate COVID-19.The change in viral SARS -CoV -2 RNA 
level as measured in NP swabs from 
baseline to Day 5.The difference in mean change of 
SARS -CoV -2 RNA level in NP swabs 
from baseline to Day 5 between 
nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients 
with a rebound in COVID -19 
symptoms and a positive rapid antigen 
test within 2 weeks following 
completion of an in itial 5 -day 
treatment course ,who have a positive 
viral RNA NP swab test result at 
baseline. This will be estimated 
without regard to study treatment 
discontinuation and without regard to 
prohibited therapies.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 13Objectives Endpoints Estimands
Secondary: Secondary: Secondary: 
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo/ritonavir on the duration of 
viral shedding.Time to 2 consecutive negative rapid 
antigen test results obtained at least 24 (-
2) h apart through Day 28.The hazard ratio for time to 2 
consecutive negative rapid antigen test 
results obtained at least 24 (-2) h apart 
through Day 28 between 
nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients 
with rebound in COVID -19 symptoms 
and a positive rapid antigen test within 
2 weeks following complet ion of an 
initial 5 -day treatment course, who 
have a positive viral RNA NP swab
test result at baseline. This will be 
estimated without regard to study 
treatment discontinuation and without 
regard to prohibited therapies.
To compare the effect of 
nirmatre lvir/ritonavir to 
placebo/ritonavir on the duration and 
severity of signs and symptoms in 
participants with mild -to-moderate 
COVID -19. Time (days) to sustained alleviation of 
all targeted signs and symptoms through 
Day 28 where sustained alleviation is 
defined as the first of 2 consecutive days 
when any symptoms scored as moderate 
or severe at baseline are scored as mild 
or absent and any symptoms scored as 
mild or absent at baseline are scored as 
absent.The hazard ratio for time to sustained 
alleviation of all targeted signs and 
symptoms through Day 28 between 
nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients  
with rebound in COVID -19 symptoms 
and a positive rapid antigen test within 
2weeks following completion of an 
initial 5 -day treatment course, who 
have a positive viral RNA NP swab 
test result at baseline. This will be 
estimated without regard to study 
treatment discontinuation and without 
regard to prohibited therapies.
To describe the safety and tolerability 
of nirmatrelvir/ritonavir i n participants 
with mild -to-moderate COVID -19.Incidence of TEAEs. Incidence of SAEs 
and AEs leading to discontinuation.Notapplicable.
Overall Design:
This Phase 2, randomized, double- blind, placebo -controlled study  will evaluate the efficacy  
and safet y of a repeat 5- day treatment course of nirmatrelvir/ritonavir or placebo/ritonavir for 
the treatment of mild -to-moderate COVID -19. Participants must have written documentation, 
such as an electronic health record, medical record, or prescription receipt of treatment with 
nirmatrelvir/ritonavir (verbal assertion of treatment is not acceptable) with patient -reported 
100% compliance (ie, completed a 5 day  cour se of nirmatrelvir/ritonavir). They  must have 
experienced alleviation or resolution in COVID -19 signs/sy mptoms followed by  a worsening 
(rebound) of signs/s ymptoms along with a positive rapid antigen test after completing an 
initial 5 -day course of nirmatre lvir/ritonavir. 
The onset of rebound in COVID -19 s ymptoms along with evidence of SARS -CoV -2 
infection must occur within 2 weeks (14 day s) after completion of an initial 5 -day course of 
nirmatrelvir/ritonavir. A 2- week time -period for rebound sy mptoms and SARS- CoV -2 
infection was selected to enroll a population that has a presumptive recurrence of the same 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 14viral illness and not a new SARS -CoV -2 infection. Sy mptom burden including alleviation, 
resolution and worsening (rebound) to qualify  for the study  is ba sed on the judgment of both
the participant along with investigator judgment.
Eligible participants for this study  will be randomly  assigned (2:1 allocation of active to 
placebo) to receive:
nirmatrelvir plus ritonavir orall y q12h for 5 days; or
placebo plus ritonavir orally  q12h for 5 day s.
Randomization will be stratified b y geographic region. 
Participants will be screened within 24 hours before randomization.  
Participants must be randomized within 48 hours from the onset of the rebound COVID -19 
symptoms and must be randomized within 24 hours of a positive baseline rapid antigen test. 
The total study  duration is up to 24 weeks, including study  intervention administration 
through Day  5 or Day  6, efficacy  and safet y assessments through Day  34, and long -term 
follow up at Weeks 12 and 24.
Participants are eligible if they  are at least 12 y ears of age (and weigh ≥40 kg at screening) 
and they  must have at least 1 characteristic or underly ing medical condition associated with 
an increased risk of developing s evere illness from COVID- 19. However, participants who 
are immunocompromised are excluded from this study  as they  may  have prolonged viral 
shedding due to their immunocompromised state. Participants will be eligible for enrollment 
irrespective of COVID -19 vaccination/boosted status (except for time course restrictions 
listed in the exclusion criteria).
An independent E -DMC will review unblinded data to ensure the safet y of participants on an 
ongoing basis throughout the duration of the stud y.
Number of Participants:
Approximately  411 participants will be enrolled in the study . 
Note: "Enrolled" means a participant's, or their legally  authorized representative’s, agreement 
to participate in a clinical study  following completion of the informed consent pro cess and 
randomization. A participant will be considered enrolled if the informed consent is not 
withdrawn prior to participating in an y stud y activity . Potential participants who are screened 
for the purpose of determining eligibility  for the study , but do not participate in the study , are 
not considered enrolled. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 15Study Population: 
Inclusion and exclusion criteria are listed below:
Inclusion Criteria 
Participants must meet the following inclusion criteria to be eligible for enrollment into the 
study :
1.Participants aged 12 years or older and weighing ≥40 kg at screening .
2. Participants must have written documentation with patient- reported 100% 
compliance (ie, completed a 5 day  course of nirmatrelvir/ritonavir). They  must 
have s ymptom alleviation or resolutio n in COVID -19 signs/s ymptoms followed 
by a worsening (rebound) of signs/s ymptoms after completing an initial 5- day 
course of nirmatrelvir/ritonavir based on the judgement of both the participant and 
investigator.
3.The onset of rebound in COVID -19 s ymptoms m ust occur within 2 weeks (14 
days) after the completion of the initial 5 -day course of nirmatrelvir/ritonavir.
4.Onset of rebound in signs/sy mptoms attributable to COVID -19 within 48 hours 
prior to randomization and ≥ 1 sign/sy mptom attributable to COVID -19 p resent on 
the day  of randomization.
5.SARS -CoV -2 infection as determined b y rapid antigen testing in an y specimen 
collected within 24 hours prior to randomization and collected within 2 weeks (14 
days) after the completion of the initial 5 -day treatment cour se of 
nirmatrelvir/ritonavir.
6.Has at least 1 characteristic or underl ying medical condition associated with an 
increased risk of developing severe illness from COVID -19.
Exclusion Criteria
Participants with any  of the following characteristics/conditions w ill be excluded:
1.Current need for hospitalization, hospitalized for the index COVI D-19 infection, 
or anticipated need for hospitalization within 24 h after randomization in the 
clinical opinion of the site investigator.
2.History  of severe chronic liver dise ase (eg, jaundice, ascites, hepatic 
encephalopath y, history of bleeding esophageal or gastric varices). No laboratory 
testing is needed.
3.History  of hypersensitivity  or other contraindication to any  of the components of 
the study  interventions, as determine d by the investigator.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 164.Suspected or confirmed concurrent active s ystemic infection other than COVID -
19 that may  interfere with the evaluation of response to the study  intervention.
5.Receiving dialy sis or eGFR <30 mL /min/1.73 m2(for adults) or eCrCl <30 
mL/min (for adolescents) at screening using creatinine point of care device.
6.Oxygen saturation of <92% on room air obtained at rest within 24 hours prior to 
randomization.
7.Immunocompromised.
8.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the 
risk of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
9. Current use of a ny prohibited concomitant medication(s).
10.COVID -19 vaccination within 14 day s prior to study  entry  or anticipated COVID -
19 vaccination through Day  34.
11.Receiving other COVID -19 specific treatments within 30 day s of randomization 
and through Day  34, excluding the initial course of nirmatrelvir/ritonavir as well 
as blinded study  medication.
12.Prior participation in this trial.
13.Current or previous administration with an investigational product (drug or 
vaccine) within 30 days (or as determined b y the local require ment) or 5 half-lives 
preceding the first dose of study  intervention used in this study (whichever is 
longer).
14.Females who are pregnant up to 14 weeks gestation. Pregnancy  ≥14 weeks is not 
exclusionary .
15.Investigator site staff directly  involved in the cond uct of the study  and their 
family  members, site staff otherwise supervised by  the investigator, and sponsor 
and sponsor delegate employ ees directl y involved in the conduct of the study  and 
their family  members.
Study Arms and Duration:
Eligible participant s for this study  will be randomly  assigned (2:1) to receive nirmatrelvir 
plus ritonavir orally  q12h or placebo/ritonavir as specified in the tables below.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 17Study Intervention(s)
Intervention Name Nirmatrelvir Placebo for nirmatrelvir Ritonavir
Arm Name
(group of participants 
receiving a specific treatment 
or no treatment)nirmatrelvir/ritonavir placebo ritonavir
Unit Dose Strength(s) 150 mg 0 mg 100 mg
Route of Administration Oral Oral Oral
Use Experimental Placebo Experimental
IMP or NIMP/AxMP IMP IMP IMP
Study Arm(s)
Arm Title Nirmatrelvir/ritonavir Placebo/ritonavir
Arm Type Experimental Other
Arm 
DescriptionParticipants will receive nirmatrelvir/ritonavir 
300mg/100 mg (or 150 mg/100 mg for participants 
with eGFR ≥30 to <60 mL/min/1.73 m2or eCrCl ≥30 
to <60 mL/min) q12h from Day 1 through Day 5.Participants will receive placebo 
0mg/ritonavir 100 mg q12h for 5 days.
Statistical Methods:
The study  will randomize approximately  411 participants in a 2:1 randomization ratio to 
nirmatrelvir/ritonavir or placebo/ritonavir.
The primary  efficacy  endpoint is the change in viral SARS -CoV -2 RNA level from baseline 
to Day  5 as measured in NP swabs. This will be estimated without regard to study  treatment 
discontinuation and without rega rd to prohibited therapies. 
With respect to the primary  endpoint of change in SARS -CoV -2 RNA level from baseline to 
Day 5 as measured in NP swab in the mITT analy sis set, and assuming a SD of 1.8 (based on 
Study  C4671005 [EPI C-HR, [STUDY_ID_REMOVED]]), a sample size of approximately  315 evaluable 
participants (210 participants in the nirmatrelvir/ritonavir group and 105 participants in the 
placebo/ritonavir group) is expected to provide 90% power to detect a difference of 0.7 log 10
copies/mL  in viral RNA between groups using a 2 -sided 0.05 alpha level test. Assuming 
approximately  10% of participants will have a negative viral RNA result at baseline, and 
assuming a non -evaluable rate of 15%, approximately  411 participants will be randomized in 
the study  to achieve approximately  315 participants evaluable for the primary  efficacy  
endpoint.
No formal interim anal ysis is planned for this study . However, the sponsor may  conduct 
unblinded reviews of the data during the course of the study  if requested b y regulatory  
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 18authorities including in the support of regulatory  submissions.  Should an unblinded review 
be requested, details of the unblinding plan will be described in the SAP and a separate data 
unblinding document.
Ethical Considerations:
Previous studies have demonstr ated efficacy , safety , and tolerability  of nirmatrelvir/ritonavir 
in adults at increased risk of progressing to severe COVID -19 illness. The FDA has granted 
EUA for nirmatrelvir/ritonavir for the treatment of mild- to-moderate COVID -19 in adults 
and pediatr ic patients (12 y ears of age and older and weighing at least 40 kg) with positive 
results of direct SARS -CoV -2 testing, and who are at high risk for progression to severe 
COVID -19, including hospitalization or death. The most common adverse events describe d 
with nirmatrelvir/ritonavir treatment are allergic reactions, change in taste, diarrhea, 
headache, and vomiting. At present, there are no controlled efficacy  and safety  data of a 
repeat 5 -day course of nirmatrelvir/ritonavir in participants with acute re bound in sy mptoms 
and SARS -CoV -2 infection. People who have rebound in mild -to-moderate COVID -19 may  
benefit from a repeat 5 -day treatment course of nirmatrelvir/ritonavir. Considering the 
measures to minimize risk to study  participants, the potential risk s identified in association 
with nirmatrelvir/ritonavir are justified b y the anticipated benefits that may be afforded to 
participants eligible for enrollment in this study . 
Participants will be expected to commit time and may experience some discomfort w hile 
undergoing study  assessments. I n addition, participants must avoid use of a non -study  
COVID -19 antiviral (excluding a single 5- day treatment course of nirmatrelvir/ritonavir for 
eligibility ), monoclonal antibody  therap y for COVID -19, or COVID -19 vacci nation within 
14 day s prior to randomization and through completion of Day  34. Participants who progress 
to severe or critical COVID -19 will however be permitted to receive specific COVID-19 
treatment(s) such as antiviral therap y or use of other treatments considered standard of care. 
Female participants who are not pregnant and are of childbearing potential must agree to use 
appropriate contraception methods.
1.2.Schema

Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 191.3.Schedule of Activities
The SoA  table provides an overview of the protocol visits and procedures. Refer to the STUDY  ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA  table, in order to conduct eva luations or 
assessments required to protect the well -being of the participant. 
Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Study Visit 
LocationS S S/P S/P S/P S/P S/P S/P S/P T T S/P Site staff should, in discussion with 
participants, determine the most appropriate 
location to conduct study visits. Visits should 
take place at the investigational site (S). If this 
is not feasible, then alternate venues may 
include the participant’s location (P).
If an in -person visit is held at a location other 
than S, the HCP performing the visit may be 
unable to complete all assessments. In t hese 
cases, a telemedicine/telehealth visit should 
also occur to perform the remaining 
assessments.
ELIGIBILITY
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 20Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Informed 
consent/assent X Informed consent/assent should be obtained 
prior to undergoing any study -specific 
procedures.
See Section 10.1.3 for additional information.
Verify 
inclusion/exclusion 
criteriaX See Section 5.1and Section 5.2.
Screening visit: A serum creatinine point- of-
care device assessment for calculating eGFR 
for adults 18 years and older, and eCrCl for 
adolescents 12 years to <18 years is required 
for eligibility ( Appendix 7 ).
Demographics and 
medical historyX See Section 8.1.1.1 .
Includes history of confirmed/presumed prior 
COVID -19 infections, including most recent 
infection, SARS -CoV -2 test results, if 
available, and COVID -19 vaccinations.
Physical 
Exam ination and 
Vital Signs
Targeted physical 
examinationX See Section 8.3.1for additional information.
Weight, height X Height may be self -reported for participants 
≥18 years of age .
See Section 8.3.1 for additional information.
Vital signs X X X X X X X See Section 8.3.2 for additional information.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 21Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Laboratory 
Assess mentsSee Section 8.3.3 for additional information.
See Appendix 2 for a list of Clinical 
Laboratory tests to be done.
For laboratory collection volumes, see the 
laboratory manual.
Hematology X X X X Baseline laboratory assessments should be 
collected prior to first dose of study 
intervention.
If deemed necessary to confirm eligibility, 
laboratory assessments at screening may be 
performed at the local laboratory at the 
investigator’s discretion.
Abnormal laboratory valued related to AEs 
should be followed until resolution.Blood chemistry X X X X
Point -of-care 
serum creatinine 
assessmentX [X] Screening visit: A serum creatinine point -of-
care device assessment for determining 
estimation of kidney function (eGFR for adults 
18 years and older, and eCrCl for adolescents 
12 years to <18 years) is required for 
eligibility. See Section 10.7 for age specific 
kidney function calculations.  
Baseline visit assessment expected only if 
screening and baseline visits are held on 
different days. If a se rum creatinine point- of-
care device assessment is performed at 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 22Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
screening and baseline, the baseline estimate 
of kidney function will determine eligibility.
See Section 8.3.2.4 .
FSH X FSH is to be performed locally to confirm 
postmenopausal status in female participants 
<60 years of age at screening who are not 
using hormonal contraception or hormonal 
replacement therapy. Female participants aged 
50 to 60 years with no menses for 12 months 
do not need FSH testing to be performed to 
confirm postmenopausal status.
See Appendix 2 .
HIV test (Germany 
only)X Local HIV testing at screening will be 
performed for participants in Germany as 
required by the German HA
See Appendix 2
Pregnancy Test X X X See Section 8.3.4 .
SARS -CoV -2 
SerologyX X X X
Biom arker 
Assess ments
NP swab collection 
for SARS -CoV -2 
RNA levelX X X X X X X X X All NP swabs of both nares, will be collected 
by HCP at visits indicated. Samples will be 
shipped to central lab for quantitative SARS-
CoV -2 RNA concentration. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 23Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
At Screening and Baseline (Day 1) only, rapid 
antigen testing can be done before NP swab 
collec tion.
At all other time points, NP swab collection 
will be collected PRIOR to the sample for 
rapid antigen testing.
See Section 8.7.1 .
Rapid antigen 
testing (on site)X X X X X X X X X X Investigative sites will use test kits provided 
by the sponsor and perform sample collection 
and testing according to manufacturer’s 
instructions.
At Screening and Baseline (Day 1) only, rapid 
antigen testing can be done before NP swab 
collection.
At all other time points rapid antigen testing 
must occur after NP swab collection.
Screening assessment performed locally, at 
site. If rapid antigen testing is performed at  
screening and baseline, th e baseline result will 
determine eligibility.
Site staff should train participants/caregiver at 
the screening/baseline visit to ensure 
participants can perform the rapid antigen test 
appropriately. The participant should perform 
the baseline rapid antigen testing assessment 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 24Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
during the visit to ensure proper sample 
collection under observation by site staff.
Will be self -collected by the participant.
See Section 8.1.3 .
See Section 8.7.3 .
Participant 
self-collected rapid 
antigen testingCollected daily and witnessed by the site staff.*   Site staff should train participants/caregiver at 
the screening/baseline visit to ensure 
participants can perform the rapid antigen test 
appropriately. The participant should perform 
the baseline rapid antigen tes ting assessment 
during the visit to ensure proper sample 
collection.
Only 1 rapid antigen test is expected to be 
performed daily. When onsite, rapid antigen 
testing will be done at the site and no self -
collected rapid antigen testing at home will be 
done.
Site staff will observe the participant 
performing the rapid antigen test (ie, via video 
or videoconferencing software if the procedure 
is conducted remotely), confirm testing, and 
record the test result in the CRF.
*Daily testing will stop once the partic ipant 
has 2 consecutive negative tests separated by 
at least 24[ -2]h. Thereafter, rapid antigen 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 25Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
testing will be done at regularly scheduled 
onsite visits.
See Section 8.1.3
Oropharyngeal 
samples for SARS -
CoV -2 RNA levelX X X X X X See Section 8.7.4 .  
Plasma collection 
for SARS -CoV -2 
RNA level X X X X X X X X X See Section 8.7.2 .
Plasma collection 
specific for 
biomarkersX X X X X X See Section 8.7.6.1 .
Retained research 
samples for 
genetics (Prep D1) X X X X X If not collected on the designated collection 
day, collect at the next available time point 
when biospecimens are being collected in 
conjunction with a participant visit.
See Section 8.6.2 .
Retained research 
samples for 
biomarkers (Prep 
B2.5, Prep R1), 
M3 (urine)X X X X X See Section 8.7.8
Study 
Intervention 
Randomization X
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 26Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Study intervention 
dispensationX Study intervention will be dispensed on Day 1. 
(See Section 6.1.1 )
See Appendix 7 for age -specific kidney 
function calculations to determine nirma trelvir 
dosing.
Study intervention 
administration Days 1 through 5 Baseline assessments should be performed 
before administration of the first study 
intervention.
The first dose of study intervention will be 
administered to all participants on Day 1 
during the in -person visit. All subsequent 
doses of study intervention will be self -
administered (or administered to the 
participant by a legal guardian or caregiver). If 
only 1 dose of study intervention is 
administered on Day 1, stu dy intervention 
should end on Day 6.
See Section 6.1.
Participant-
completed study 
intervention logDaily on Days 1 through 
5Participants will use a participant -completed 
electronic dosing diary to record the date and 
time of their study intervention dosing.
Study intervention log should be completed 
daily on Days 1 through 6 if only 1 dose was 
administered on Day 1.
See Section 6.5.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 27Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Staff review of 
study intervention 
logDaily on Days 1 through 
5Staff review of the study intervention log 
should be completed daily on Days 1 through 
6 if only 1 dose was administered on Day 1.
See Section 6.
Study 
Intervention 
Accountability
Retrieval of 
unused study 
intervention and 
empty study 
intervention 
containersX If the last dose of study intervention is taken 
on Day 6, collect at next visit.
Study intervention 
accountabilityX Study intervention accountability is only 
performed at the Day 10 visit if the last dose 
of study intervention is taken on Day 6.
Patient Reported 
Outcomes
Participant-
completed study 
diary (COVID -19 
signs and 
symptoms)Collected daily from Days 1 through 28. See Section 8.2.3.5 .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 28Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Collection of 
global impression 
questionsCollected daily from Days 1 through 28. Participants will answer 3 global impression 
questions. The global impression questions 
will be answered after the completion of the 
COVID -19 signs and symptoms diary is 
completed.
See Section 8.2.3.1 .
SF-36 v2 Health 
Survey (Acute 
Form)X X X X Only adult participants ( ≥18 years of age at the 
time of screening) will be asked to complete 
the SF -36. See Section 8.2.3.2 .
WPAI X X X X Only adult participants ( ≥18 years of age at the 
time of screening) will be asked to complete 
the WPAI. See Section 8.2.3.3
EQ-5D-5L X X X X X X Only adult participants (≥18 years of age at the 
time of screening ) will be asked to complete 
the EQ -5D-5L. See Section 8.2.3.4 . 
Study Procedures 
and Assessments
Provide 
participants with 
study emergency 
contact cardX See Section 10.1.11 .
Collect/update 
secondary contactsX X See Section 8.1.1.2 .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 29Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Record/update 
household 
characteristicsX X X X X X X X See Section 8.1.2 .
Record COVID -
19-related medical 
visitsX
X X X X X X X COVID -19-related medical visits a participant 
has attended since the last assessment will be 
collected.
See Section 8.2.2 .
Contraception 
checkX X X X X X X X X X See Section 5.3.1 and Appendix 4 . 
Prior/concomitant 
therapyX X X X X X X X X X All prescription and over-the -counter 
medications including vaccines taken by the 
participant within 30 days before study entry 
(considered prior treatment) will be recorded. 
Includes documentation along with start/stop 
dates of recent nirmatrelvir/ritonavir.
See Section 6.9.
COVID -19 
adjunctive 
therapeutic 
proceduresX X X X X X X X X X Nondrug treatments will be collected through 
the Day 34 visit or at the ET visit.
COVID -19 signs 
and symptomsX X See Section 8.2.3.5 .
Vital Status Check X X Verify mortality status of participants.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 30Table 1.Study Schedule of Assessment
Visit Identifier Screen Treat ment Period Efficacy and Safety Follow -up Period LTFU Notes
Abbreviations used 
in this table may 
be found in 
Appendix 12 .Baseline 
(Day 1)Day 3 Day 5 Day 10 Day 15 Day 21 Day 28 Day 34 Week 
12Week 
24ET 
(prior 
to Day 
34)Day relative to start of study intervention 
(Day  1).
Baseline (Day 1) visit is a mandatory visit.
Assessments indicated in brackets [X] are only 
to be conducted if indicated as described in the 
“Notes”.
Visit Window Day -1 to 
Day 1 0 days ±1 day ±1 
day±1 day ±2 
days±2 
days±2 days ±3 days ±7 
days±7 
days±5 days Screening procedures may be done from Day -
1 to Day 1 and may be completed on the same 
calendar day as Baseline/Day 1 procedures. If 
screening and baseline visits are conducted on 
the same calendar day, assessments and 
procedure that are listed to occur at both visits 
only need to be completed once.
Serious and 
nonserious AE 
monitoringX X X X X X X X X X AEs should be assessed by means of a 
telemedicine visit if an in -person visit is not 
feasible.
Previously identified AEs (either by interview, 
physical exam, or other assessment) should be 
monitored to the extent possible if 
telemedicine is used.
See Section 8.4.3 for follow -up AE and SAE 
assessments.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 312.INTRODUCTION
Nirmatrelvir, a potent and selective SARS- CoV -2 3CL  orall y administered protease inhibitor, 
is being investigated in participants with rebound of COVID -19 s ymptoms and rapid antigen 
test positivity .
2.1.Study Rationale 
Case reports in the literature describe individuals who have experienced s ymptomatic 
relapses of SARS -CoV -2 infection fol lowing completion of a 5 -day course of 
nirmatrelvir/ritonavir [1-3]. In the available cases, patients are described as experiencing rapid 
improvement in sy stemic sy mptoms following initiation of treatment but then experience a 
rebound in COVID -
19 sy mptoms after completing therap y. The time course of symptom 
rebound suggests that s ymptom recurrence is likely  not related to re
-exposure and that it does 
not reflect a potential re -infection event. In one case report, s ymptom relapse was 
accompanied b y fluctuating RT- PCR cy cle thresholds and antigen testing suggesting the 
potential for a rebound in viral replication. In a separate case series of 7 patients with 
recurrent s ymptoms, median SARS -CoV -2 RNA at baseline was 6.1 log 10copies/mL  (range 
4.2-7.3) and enrollment viral cultures were positive in 3 of 7 individuals [4]. Several of the 
published case reports on sy mptom recurrence included viral sequencing and these reports to 
date have not identified resistance mutations to nirmatrelvir.
A retrospective review of 483 high -risk patients treate d with nirmatrelvir/ritonavir reported 
4(0.8%) of patients experienced rebound of s ymptoms. Median time to rebound was 
reported as 9 day s. Rebound sy mptoms were characterized as mild and resolving without 
additional COVID -19 therapy  with no patient requir ing hospitalization[ 5].
Post-treatment increases in SARS -CoV -2 RNA levels (ie, viral RNA rebound) in 
nasophary ngeal samples were observed on Day  10 or Day  14 in a subset of 
nirmatrelvir/ritonavir and placebo recipients in the EPI C-HR study . The frequency  of
detection of post -treatment viral RNA rebound varied according to anal ysis parameters but 
was generall y similar among nirmatrelvir/ritonavir and placebo recipients, regardless of the 
rebound definition used. For participants who showed a half -log 10or gre ater increase relative 
to end of treatment and whose viral load was persistent through follow -up, the occurrence 
was 1.73% placebo and 2.32% nirmatrelvir/ritonavir. In addition to these, some participants 
had transient half -log 10or greater increases relative to end of treatment, the occurrence was 
2.35% in placebo vs 4.65% nirmatrelvir/ritonavir. A similar or smaller percentage of placebo 
recipients compared to nirmatrelvir/ritonavir recipients had nasophary ngeal viral RNA 
results <LLOQ at all study timepo ints in both the treatment and post- treatment periods. Post -
treatment viral RNA rebound was not associated with the primary  clinical outcome of 
COVID -19-related hospitalization or death from any  cause through Day  28 following the 
single 5 -day course of nir
matrelvir/ritonavir treatment. Post- treatment viral RNA rebound 
also was not associated with drug resistance as measured b y mPro sequencing. The clinical 
relevance of post -treatment increases in viral RNA following nirmatrelvir/ritonavir or 
placebo treatme nt is unknown. 
At present, there are no controlled efficacy  and safety  data of a repeat 5 -day course of 
nirmatrelvir/ritonavir in participants with acute rebound in sy mptoms and SARS -CoV -2 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 32infection. Recurrence in sy mptoms along with a positive rapid anti gen test following the 
completion of a 5 -day course of nirmatrelvir/ritonavir may  indicate that these patients require 
additional therap y to achieve sustained viral clearance. Such patients may benefit from an 
additional 5- day treatment duration. The purpo se of this study  is to evaluate the efficacy , 
safet y and tolerability of a second 5 -day treatment course of nirmatrelvir/ritonavir in 
participants with a rebound in COVI D
-19 s ymptoms and a positive rapid antigen test within 
2 weeks (14 day s) following comp letion of an initial 5 -day treatment course.
2.2.Background 
COVID -19, caused b y the SARS -CoV -2 coronavirus, was declared a global pandemic b y the 
WHO on 11 March 2020 [6], and continues to be a serious global threat to public health and 
to health care s ystems. As of 07 March 2022, COVID
-19 has infected at least 446 million 
people, and has led to at least 6 million deaths worldwide[ 7]. 
In order to prevent SARS -CoV -
2 infection, several COVID- 19 vaccines have been approved 
or authorized for emergency  use by  Health Authorities and are being administered 
globall y[8]. 
In December 2021, the FDA granted EUA for a 5 day  course of treatment for 2 separate oral 
antiviral agents, nirmatrelvir/ritonavir [9]and molnupiravir [10], for the treatment of COVID -
19 in adult and pediatric patients 12 y ears of age and older who weigh at least 40 kg, with 
mild to moderate COVID -19 who are at high risk for progressing to severe illness. I n January  
2022, remdesivir received approval for this same population
[11]. This treatment is 
administered b y IV infusion over 3 days for nonhospitalized patients with mild to mode rate 
COVID -19 who are at high risk for progressing to severe illness.
In this stud y of participants with rebound of COVID -19 s ymptoms and rapid antigen test 
positivity , nirmatrelvir/ritonavir will be administered for 5 day s.
2.2.1. Clinical Overview
The safet y and efficacy  of a 5 -day treatment with nirmatrelvir/ritonavir in adults was 
demonstrated in Study  C4671005, which enrolled nonhospitalized sy mptomatic adults with 
laboratory -confirmed diagnosis of SARS -CoV -2 infection with at least 1 risk factor for 
progress ion to severe disease and with a COVID- 19 sy mptom onset of ≤5 day s. In the 
analysis of the primary  endpoint from all participants enrolled in Study  C4671005, an 89% 
reduction in COVID -19-related hospitalization or death from an y cause compared with 
placebo in participants treated within 3 day s of symptom onset was observed. 0.72% of 
participants who received nirmatrelvir/ritonavir were hospitalized through Day  28 following 
randomization (5 of 697 hospitalized with no deaths), compared to 6.45% of participants who 
received placebo and were hospitalized or died (44 of 682 hospitalized with 9 subsequent 
deaths) (p<0.001). In the final anal ysis of participants who initiated treatment ≤ 5 day s from 
symptom onset and did not receive or were not expecte d to receive COVID -19 therapeutic 
mAbs treatment at time of randomization (mI TT1 population), nirmatrelvir/ritonavir 
significantl y reduced COVID -19‒related hospitalization or death from 66/1046 (6.31%) to 
9/1039 (0.87%) compared with placebo at Day  28 (p<0.0001), corre sponding to an 86.3% 
relative risk reduction.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 33Refer to the IB [12]for more details on studies, including clinical efficacy , safet y, and PK 
results for completed and ongoing studies.
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of nirmatrelvir/ritonavir 
may be found in the IB, which is the SRSD for this 
study .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 342.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) Nirmatrelvir
Emesis In Study C4671005, vomiting occurred at a 
greater frequency in the nirmatrelvir/ritonavir 
group (1.1%) than in the placebo group (0.8%).AEs will be monitored and participants may 
receive antiemetics if needed.
Hypertension Transient increases in systolic, diastolic, and 
mean blood pressure were observed in the 
preclinical studies. In Study C4671005 (adults at 
high risk for severe disease), a small imbalance 
in hypertension AEs (1% vs <1%) w as reported.Vital signs and all AEs will be monitored in the 
study.
Reduced maternal and fetal weight In rabbit embryo -fetal development toxicity 
studies, nirmatrelvir -related lower maternal body 
weight change and food consumption were 
observed at 1000 mg/kg/day but were not 
considered adverse based on low  magnitude of 
difference from control and lack of impact on 
absolute body weights. Nirmatrelvir -related, 
adverse, lower fetal weight (0.91x control) w as 
observed at 1000 mg/kg/day.Lower dose of 300 mg q12h (or 150 mg q12h in 
moderate renal impairment) is used in this study.
Study Intervention(s) Ritonavir
Gastrointestinal disturbances (including diarrhea, 
nausea, vomiting and abdominal pain)Frequently reported adverse reaction in HIV 
positive patients who are HIV -positive at 600 mg 
BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observatio n of AEs.
Taking study intervention with food may improve 
tolerability.
Neurological disturbances (eg, paresthesia, 
including oral paresthesia, dysgeusia and 
dizziness)Frequently reported adverse reaction in patients 
who are HIV- positive at 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs.
Rash (most commonly reported as erythematous 
and maculopapular, followed by pruritic)Frequently reported adverse reaction in patients 
who are HIV- positive at 600 mg BID.Lower dose us ed in this study. There w ill be close 
observation of AEs and monitoring through 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 35Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
targeted physical exams. If needed, therapeutic 
interventions per SoC may be provided.
Fatigue/Asthenia Frequently reported adverse reaction in patients 
who are HIV- positive a t 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 362.3.2. Benefit Assessment 
Nirmatrelvir/ritonavir has been shown to have SARS- CoV -2 antiviral activity  in vitro. 
Efficacy , safety  and tolerability  of nirmatrelvir/ritonavir was demonstrated in adults at 
increased risk of progressing to severe COVID -
19 illness. The EMA has granted marketing 
authorisation approval for nirmatrelvir/ritonavir for the treatment COVID -19 in adults who 
do not require supplemen tal oxy gen and who are at increased risk for progressing to severe 
COVID -19[13].The FDA has granted EUA for nirmatrelvir/ritonavir for the treatment of 
mild to moderate COVID -19 in adults and pediatric patients (12 years of age a nd older and 
weighing ≥40 kg) with positive results of direct SARS -CoV -2 testing, and who are at high 
risk for progression to severe COVID -19, including hospitalization or death.
2.3.3. Overall Benefit/Risk Conclusion
Considering the current COVID -19 global pande
mic, the high burden of both mortality  and 
morbidity , the potential for future epidemic outbreaks, the lack of readil y available outpatient 
treatment options, and the measures taken to minimize risk to study  participants, the potential 
risks identified in association with nirmatrelvir/ritonavir are justified by  the anticipated 
benefits that may  be afforded to participants with rebound of COVID -19 sy mptoms and rapid 
antigen test positivity . Rebound in sy mptoms along with a positive rapid antigen test 
followi ng the completion of a 5 -day course of nirmatrelvir/ritonavir may  indicate that these 
patients may  require additional therapy  to achieve sustained viral clearance. Such patients 
may benefit from an additional 5 -day treatment duration.
3.OBJECTIVES, ENDPOINT S, AND ESTIMANDS 
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo /ritonavir on viral RNA level 
in NP swabs in participants with 
mild-to-moderate COVID-19.The change in viral SARS -CoV -2 
RNA level as measured in NP swabs 
from baseline to Day 5.The difference in mean change of 
SARS -CoV -2 RNA level in NP 
swabs from baseline to Day 5 
between nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients 
with a rebound in COVID -19 
symptoms and a positive rapid 
antigen test within 2 weeks 
following completion of an initial 
5-day treatment course ,who have a 
positive viral RNA NP swab test 
result at baseline. This will be 
estimated without regard to study 
treatment discontinuation and
without regard to prohibited 
therapies.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 37Objectives Endpoints Estimands
Secondary: Secondary: Secondary: 
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo/ritonavir on the duration of 
viral shedding.Time to 2 consecutive negative rapid 
antigen test results obtained at least 
24(-2) h apart through Day 28.The hazard ratio for time to 2 
consecutive negative rapid antigen 
test results obtained at least 24 (- 2) h 
apart through Day 28 between 
nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients 
with rebound in COV ID-19 
symptoms and a positive rapid 
antigen test within 2 weeks following 
completion of an initial 5 -day 
treatment course, who have a positive 
viral RNA NP swab test result at 
baseline. This will be estimated 
without regard to study treatment 
discontinuati on and without regard to 
prohibited therapies.
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo/ritonavir on the duration and 
severity of signs and symptoms in 
participants with mild -to-moderate 
COVID -19. Time (days) to sustained alleviation of
all targeted signs and symptoms 
through Day 28 where sustained 
alleviation is defined as the first of 
2consecutive days when any 
symptoms scored as moderate or 
severe at baseline are scored as mild or 
absent and any symptoms scored as 
mild or absent at b aseline are scored as 
absent.The hazard ratio for time to sustained 
alleviation of all targeted signs and 
symptoms through Day 28 between 
nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients 
with rebound in COVID -19 
symptoms and a positive rapid
antigen test within 2 weeks following 
completion of an initial 5 -day 
treatment course, who have a positive 
viral RNA NP swab test result at 
baseline. This will be estimated 
without regard to study treatment 
discontinuation and without regard to 
prohibited therapies.
To describe the safety and 
tolerability of nirmatrelvir/ritonavir 
in participants with mild-to -
moderate COVID -19.Incidence of TEAEs. Incidence of 
SAEs and AEs leading to 
discontinuation.Notapplicable.
Tertiary/Exploratory: Tertiary/Exploratory: Tertiary/Exploratory:
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo/ritonavir on viral RNA level 
in NP swabs in participants with 
mild-to-moderate COVID-19.Proportion of participants with SARS -
CoV -2 RNA in NP swab below the 
LLOQ on Days 3, 5, 10, 15, 21, 28, 
and 34.
Proportion of participants with 
sustained NP swab SARS -CoV -2 RNA 
below the LLOQ (defined as 
<2.0 log10copies/mL) from Day 5 
through Day 34.
Proportion of participants with 
SARS -CoV -2 RNA in NP swabs below 
the LLOQ (defined as <2.0 log10 
copies/mL) on both Days 5 and 10.
The change in SARS -CoV -2 RNA 
level in NP swabs from baseline to 
Days 3, 10, 15, 21, 28, and 34.
Time to sustained NP swab 
SARS -CoV -2 RNA below the LLOQ 
(defined as <2.0 log10copies/mL) and Not applicable.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 38Objectives Endpoints Estimands
remains below the LLOQ through Day 
34 for participants with NP swab 
SARS -CoV -2 RNA greater than or 
equal to the LLOQ at baseline.
Rebound in SARS -CoV -2 RNA level 
in NP swabs at follow -up (ie, any study 
visit from Day 10 to through Day 34, 
defined as a half ( 0.5) log 10copies/mL 
increase or greater in SARS -CoV -2 
RNA level relative to SARS -CoV -2 
RNA level on Day 5 and with a 
follow -up viral RNA level 
≥2.5log 10copies/mL.
To compare the effect of 
nirmatrelvir/ritonavir on the rate of 
cell culture infectious virus over 
time in participants with mild-to -
moderate COVID-19In participants with detectable viral titers 
at baseline by TCID50:
Time to negative infectious titer by 
TCID50.
Change in TCID50 from baseline to 
Days 3, 5, 10, 15, 21, 28, and 34.
Proportion of participants with 
negative infectious titer by TCID50 
on Days 3, 5, 10, 15, 21, 28, and 34.
In participants with positive viral titers at 
baseline by virus recovery:
 Time to negative infectious titer by 
virus recovery.
 Proportion of participants with 
negative infectious titer by virus 
recovery on Days 3, 5, 10, 15, 21, 
28, and 34.Not applicable
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo /ritonavir on viral 
concentration in plasma in 
participants with mild -to-moderate 
COVID -19.Change from baseline in SARS-CoV -2 
viral RNA level in plasma, over time.Not applicable.
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo/ritonavir on COVID -19-
related hospitalization and all -cause 
mortality in participants with mild -
to-moderate COVID -19.Proportion of participants with 
COVID -19-related hospitalization >24 
h or death from any cause through 
Day 28.Not applicable.
To compare the effect o f 
nirmatrelvir/ritonavir to 
placebo/ritonavir on COVID -19-
related healthcare resource 
utilization in participants with mild -
to-moderate COVID -19.Number of COVID-19-related medical 
visits through Day 34.Not applicable.
To compare the effect of 
nirmatrelvir/ritonavir to 
placebo/ritonavir on the duration and 
severity of signs and symptoms in 
participants with mild -to-moderate 
COVID -19.Time (days) to sustained resolution of 
all targeted signs and symptoms 
through Day 28 where sustained 
resolution is defined as the first of two 
consecutive days when all targeted 
COVID -19 symptoms are scored as 
absent.  Not applicable
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 394.STUDY DESIGN
4.1.Overall Design
This Phase 2, randomized, double- blind, placebo -controlled study  will evaluate the efficacy  
and safet y of a repeat 5- day treatment course of nirmatrelvir/ritonavir or placebo/ritonavir for 
the treatment of mild -to-moderate COVID -19. Participants must have written documentation, 
such as an electronic health record, medical record, or prescription receipt of treatment with 
nirmatrelvir/ritonavir (verbal assertion of treatment is not acceptable) with patient -reported 
100% compliance (ie, completed a 5 day  cour se of nirmatrelvir/ritonavir). They  must have 
experienced alleviation or resolution in COVID -19 signs/sy mptoms followed by  a worsening 
(rebound) of signs/s ymptoms along with a positive rapid antigen test after completing an 
initial 5 -day course of nirmatre lvir/ritonavir. The onset of rebound in COVID- 19 sy mptoms 
along with evidence of SARS- CoV -2 infection must occur within 2 weeks (14 day s) after
completion of an initial 5- day course of nirmatrelvir/ritonavir. 
Eligible participants for this study  will be randomly  assigned (2:1 allocation of active to 
placebo) to receive:
nirmatrelvir plus ritonavir orall y q12h for 5 days; or
placebo plus ritonavir orally  q12h for 5 day s.
Randomization will be stratified b y geographic region. 
Participants will be screened within 24 hours before randomization. 
Participants must be randomized within 48 hours from the onset of the rebound COVID -
19 
symptoms and must be randomized within 24 hours of a positive baseline rapid antigen test. 
The total study  duration is up to 24 we eks, including stud y intervention administration 
through Day  5 or Day  6, efficacy  and safet y assessments through Day  34, and long -term 
follow up at Weeks 12 and 24.   
Participants are eligible if they  are at least 12 y ears of age (and weigh ≥40 kg at screening) 
and have at least 1 characteristic or underly ing medical condition associated with an 
increased risk of developing severe illness from COVID -19. However, participants who are 
immunocompromised are excluded from this study as they  may  have prolon ged viral 
shedding due to their immunocompromised state[ 14,15] . Participants will be eligible for 
enrollment irrespective of COVID -
19 vaccination/boosted status (except for time course 
restrictions listed in the exclusion criteria).
An independent E- DMC will review unblinded data to ensure the safet y of participants on an 
ongoing basis throughout the duration of the stud y.
The primary  anal ysis will be performed after all participants have completed the Day  34 
visit. The follow -up analy sis will be pe rformed after all participants have completed the 
Week 24 visit.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 404.2.Scientific Rationale for Study Design
Case reports in the literature describe individuals who have experienced s ymptomatic 
relapses of SARS -CoV -2 infection following completion of a 5 -day course of 
nirmatrelvir/ritonavir [1-3]. In the available cases, patients are described as experiencing rapid 
improvement in sy stemic sy mptoms following initiation of treatment but then experience a 
rebound in COVID -
19 symptoms after completing therap y. The time course of symptom 
rebound suggests that s ymptom recurrence is likely  not related to re-exposure and it does not 
reflect a potential re -infection event.  
In Stud y C4671005 (EPIC -HR; [STUDY_ID_REMOVED]), post- treatment increases in SARS -CoV -2 
RNA shedding levels (ie, viral RNA rebound) in nasophary ngeal samples were observed on 
Day 10 and/or Day  14 in a subset of nirmatrelvir/ritonavir and placebo recipients, 
irrespective of COVID -19 sy mptoms. The frequency  of detection of post -treatment viral 
RNA rebou nd varied according to analy sis parameters but was generally  similar among 
nirmatrelvir/ritonavir and placebo recipients, regardless of the rebound definition used. A 
similar or smaller percentage of placebo recipients compared to nirmatrelvir/ritonavir 
recipients had nasopharyngeal viral RNA results <LLOQ at all study  timepoints in both the 
treatment and post -treatment periods [9].
Post-treatment viral RNA rebound was not associated with the primary  clinical outcome of 
COVID -
19-related hospitalization or death from any  cause through Day  28 following the 
single 5 -day course of nirmatrelvir/ritonavir treatme nt. Post -treatment viral RNA rebound 
also was not associated with drug resistance as measured b y Mpro sequencing. The clinical 
relevance of post -
treatment increases in viral RNA following nirmatrelvir or placebo 
treatment is unknown [9].
At present, there are no controlled efficacy  and safety  data of a repeat 5 -day course of 
nirmatrelvir/ritonavir in participants with acute rebound in symptoms and SARS -CoV - 2 
infection. Rapid rebound in sy mptoms along with a positive rapid antigen test following the 
completion of a 5 -day course of nirmatrelvir/ritonavir may  indicate that these patients require 
additional the rapy to achieve sustained viral clearance. Such patients may benefit from an 
additional 5- day treatment duration. The purpose of this study  is to evaluate the efficacy , 
safet y and tolerability of a second 5 -day treatment course of nirmatrelvir/ritonavir in
participants with a rebound in COVI D
-19 s ymptoms and a positive rapid antigen test within 
2 weeks following completion of an initial 5- day treatment course that a participant received 
as part of routine clinical care.
A 2-week time -period for rebound s ymptoms and SARS -CoV -2 infection was selected to 
enroll a population that has a presumptive recurrence of the same viral illness and not a new 
SARS -CoV -2 infection. Sy mptom burden including alleviation, resolution and worsening 
(rebound) to qualify  for the st udy is based on the judgment of both the participant along with 
investigator judgment.
In order to avoid potential unblinding given the characteristic taste disturbance AEs 
associated with ritonavir, all participants in this study  will receive ritonavir an d be randoml y 
assigned to either nirmatrelvir or placebo. 100 mg ritonavir will be administered in the 
nirmatrelvir placebo group to match the 100 mg ritonavir in the active treatment group.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 41Ritonavir is an inhibitor of CYP3A4 and may  increase plasma concentrations of drugs that 
are primarily  metabolized by  CYP3A4. In order to avoid potential unblinding due to the 
magnitude of drug -drug interactions, all participants in this trial will receive ritonavir, and be 
randomly  assigned to either nirmatrelvir or pl acebo.   
4.2.1. Choice of Contraception/Barrier Requirements
Human reproductive safety  data are limited for nirmatrelvir/ritonavir, but there is no 
suspicion of human teratogenicity  based on the intended pharmacology of the 
compound. Therefore, the use of a highl y effective method of contraception is required for 
female participants who are not pregnant on study entry  (see Appendix 4 ).
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example , provide greater understanding of the study  intervention.
4.2.3. Inclusion of Pediatric Participants
This study  includes participants of 12 y ears of age and older and weighing ≥40 kg, which is 
consistent with the Fact Sheet for nirmatrelvir/ritonavir where FDA h as granted EUA for the 
treatment of mild -to-moderate COVID -19 in adults and pediatric patients (12 y ears of age 
and older and weighing ≥40 kg) [16].
4.3.Justification for Dose
On 22 December 2021, the US FDA granted EUA to nirmatrelvir/ritonavir for the treatment 
of mild -to-moderate COVID -19 in adults and pediatric patients (12 y ears of age or older 
weighing at least 40 kg) who are at risk for progress ion to severe disease. The recommended 
dose is 300 mg nirmatrelvir co -administered with 100 mg ritonavir q12h for 5 day s for 
subjects with normal renal function or mild renal impairment. This dose was well tolerated in 
Study  C4671005 and reduced the rate o
f hospitalization or death by  89% compared with 
placebo in s ymptomatic adult participants with COVID -19 who were at increased risk of 
progression to severe disease. 
Results from the renal impairment study  showed that the adjusted geometric mean (90% CI) 
test/reference ratios comparing moderate renal impairment (test) to normal renal function 
(reference) for nirmatrelvir AUC infand C maxwas 187.40% (148.52%, 236.46) and 138.12% 
(113.18%, 168.55%), respectively. Due to the increase in in exposures of nirmatr elvir in 
those with moderate renal impairment, and verified by  modeling and simulation, the 
nirmatrelvir/ritonavir dose in patients with moderate renal impairment was reduced to 150 
mg/100 mg q12h. 
4.4.End of Study Definition
The end of the stud y is defined a s the date of the last visit of the last participant in the study .
A participant is considered to have completed the study  if they  have completed all periods of 
the study , including the last visit.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 425.STUDY POPULATION
This study  can fulfill its objectives onl y if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. If a 
prescreening tool is utilized for stud y recruitment purposes, it will include collection of 
information that reflects t he enrollment of a diverse participant population including, where 
permitted under local regulations, age, sex, race, and ethnicity . The following eligibility  
criteria are designed to select participants for whom participation in the study  is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Participants aged 12 years or older and weighing ≥40 kg at screening (Section 10.10.1).  
Refer to 
Appendix 4 for reproductive criteria for female ( Section 10.4.1) 
participants.
Disease Characteristics:
2.
Participants must have written documentation with patient- reported 100% compliance (ie, 
completed a 5 day  course of nirmatrelvir/ritonavir). They  must have s ymptom alleviation 
or resolution in COVID -19 signs/sy mptoms followed by  a worsening (rebound) of 
signs/sy mptoms after completing an ini tial 5 -day course of nirmatrelvir/ritonavir based 
on the judgement of both the participant and investigator ( Section 10.10.2).
3.The onset of rebound in COVID -
19 symptoms must occur within 2 weeks (14 day s) after 
the completion of the initial 5- day course of nirmatrelvir/ritonavir.
4.Onset of rebound in signs/sy mptoms attributable to COVID -19 within 48 hours prior to 
randomization and ≥1 sign/sy mptom attributable to COVID -19 present on the day  of 
randomization (Section 10.10.2 ).
5.SARS -CoV -2 infection as determined by rapid antigen testing in an y specimen collected 
within 24 hours prior to randomization and collected within 2 weeks (14 days) after the 
completion of the initial 5 -day treatment course of nirmatrelvir/ritonavir.
6.Has at least 1 characteristic or underl ying medical condition associated with an increased 
risk of developing severe illness from COVID -19 (Section 10.10.4).
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 435.2.Exclusion Crit eria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Current need for hospitalization, hospitalized for the index COVI D-19 infection, or 
anticipated need for hospitalization within 24 h after randomizati on in the clinical opinion 
of the site investigator.
2.History  of severe chronic liver disease (eg, jaundice, ascites, hepatic encephalopathy , 
history  of bleeding esophageal or gastric varices). No laboratory testing is needed.
3.History  of hypersensitivity  orother contraindication to any  of the components of the 
study  interventions, as determined by  the investigator.
4.Suspected or confirmed concurrent active s ystemic infection other than COVID -19 that 
may interfere with the evaluation of response to the study  intervention.
5.Receiving dialy sis or eGFR <30 mL /min/1.73 m2(for adults) or eCrCl <30 mL /min (for 
adolescents) at screening using creatinine point of care device (see Section 10.7.1 for 
age-specific kidney  function calculation).
6.Oxygen saturation of <92% on room air obtained at rest within 24 hours prior to 
randomization ( Section 10.10.4 ).
7.Immunocompromised ( Section 10.10.7).
8.Other medical or psy chiatric condition including recent (within the past y
ear) or active 
suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk of study  
participation or, in the investigator’s judgment, make the participant inappropriate for the 
study .
Prior/Concomitant Therapy:
9.Current use of an y prohibited concomitant medication(s) (see Section 6.9; Appendix 8,
and Section 10.10.6).
10.COVID -19 vaccination within 14 day s prior to study  entry  or anticipated COVID -
19 
vaccination through Day  34.
11.Receiving other COVID -19 specific treatments within 30 day s of randomization and 
through Day  34, excluding a single 5 -day treatment course of nirmatrelvir/ritonavir as 
well as blinded study  medication ( Section 10.10.6).
Prior/Concurrent Clinical Study 
Experience:
12.Prior participation in this trial.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 4413. Current or previous administration with an investigational product (drug or vaccine) 
within 30 days (or as determined by  the local requirement) or 5 half-lives preceding the 
first dose of study  intervention used in this study  (whichever is longer). 
Other Exclusion Criteria:
14.Females who are pregnant up to 14 weeks gestation. Pregnancy  ≥14 weeks is not 
exclusionary .
15.Investigator site staff directly  involved in the conduct of the study  and their family  
members, site staff otherwise supervised b y the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study  and their family  
members.
5.3.Lifestyle Considerations
5.3.1. Contracep tion
All female participants who are not pregnant at study  entry , and who in the opinion of the 
investigator, are biologically  capable of having children must agree to use a highl y effective 
method of contraception consistently  and correctly  for at least 2 8 day s after the last study  
intervention.
Note: If the childbearing potential changes after start of the stud y (eg, a premenarchal female 
participant experiences menarche) or the risk of pregnancy  changes (eg, a female participant 
who was not heterosexuall y active becomes active), the participant must discuss this with the 
investigator, who should determine if a female participant must begin a highly  effective 
method of contraception. If reproductive status is questionable, additional evaluation should 
be considered.
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contra ception methods (see Section 10.4.3) and 
will confirm that the participant has been instructed in its consistent and correct use. At time 
points indicated in the SoA, the investigator or designee will inform the participant of the 
need to use highly  effective contraception consistently
 and correctly  and document the 
conversation and the participant’s affirmation in the participant’s chart. Participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception, 
considering that their risk for pregnancy  may  have changed since the last visit. 
In addition, the investigat or or designee will instruct the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol- specified method, including if the participant will no longer use abstinence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 455.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the st udy. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demo graph y, screen failure details, and an y SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  
not be rescreened.  
To assist in further understanding rebound, the following screen failure information will be 
captured in the eCRF and included in the study  report.
Number (%) of participants with rebound sy mptoms at time of screening but who 
are negative b y rapid antigen testing at screening and therefore screen fail for the 
study .
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administration of 
Study Intervention
Not applicable.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  interventions are all prespecified investigational and noninvestigational medicinal 
products/auxiliary  medicinal products, medical devices, and other interventions (eg, surgical 
and behavioral) intended to be administered to the study  participants during the study  
conduct.
For the purposes of this protocol, study  intervention refers to nirmatrelvir 150 mg tablets and 
matching p
lacebo and ritonavir 100 mg capsules.
6.1.Study Intervention(s) Administered
Study  intervention will be self -administered by  the participant OR administered to the 
participant b y a legal guardian or caregiver.
A legal guardian or caregiver may  administer study medication. Study  personnel should 
review dose administration requirements with the participant, and, as appropriate, with the 
delegated caregiver(s) (may  include school nurse) before administration and throughout the 
study  as necessary .
Study Intervention(s)
Intervention Name Nirm atrelvir Placebo for nirmatrelvir Ritonavir
Arm  Nam e
(group of participants 
receiving a specific nirmatrelvir/ritonavir placebo ritonavir
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 46Study Intervention(s)
treatm ent or no 
treatm ent)
Type drug placebo drug
Dose Form ulation tablet tablet capsule
Unit Dose Strength(s) 150 mg 0 mg 100 mg 
Dosage Level(s) 300 mg q12h for 5 days
150 mg q12h for 5 days 
(for participants with 
eGFR ≥30 to <60 
mL/min/1.73 m2(or 
eCrCl ≥30 to 
<60mL/min) at 
screening)0 mg q12h for 5 days 100 mg q12h for 5days
Route of 
AdministrationOral Oral Oral
Use Experimental Placebo Experimental
IMP or NIMP/AxMP IMP IMP IMP
Sourcing Provided centrally by 
the sponsor.
Refer to the IPM.Provided centrally by 
the sponsor.
Refer to the IPM.Provided centrally by the 
sponsor.
Refer to the IPM.
Packaging and 
LabelingStudy intervention will 
be provided in blister 
wallets. Each wallet will 
be labeled as required 
per country requirement. 
Products will be 
provided with blinded 
labels.Study intervention will 
be provided in blister 
wallets. Each wallet will 
be labeled as required 
per country requirement. 
Products will be 
provided with blinded 
labels.Study intervention will 
be provided in HDPE 
bottles. Each bottle w ill 
be labeled as required per 
country requiremen t. 
Products will be provided 
with open labels.
Current/Former 
Nam e(s) or Alias(es)PF-07321332 NA ritonavir
Study Arm(s)
Arm  Title Nirm atrelvir/ritonavir Placebo/ritonavir
Arm  Type Experimental Other
Arm  
DescriptionParticipants will receive 
nirmatrelvir/ritonavir 300 mg/100 mg (or 
150mg/100 mg for participants with Participants will receive placebo 0 mg/ritonavir 
100 mg q12h fo r 5 days.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 47eGFR ≥30 to <60 mL/min/1.73 m2or 
eCrCl ≥30 to <60 mL/min) q12h from 
Day 1 through Day 5.
Associated 
Intervention 
LabelsNirm atrelvir/ritonavir Placebo/ritonavir
6.1.1. Administration
The first dose of study intervention will be administered at the site. 
Nirmatrelvir 150 mg tablets or placebo for nirmatrelvir will be administered with ritonavir 
100 mg for 5 day s. Participants will be dispensed 1 blister wallet card of nirmatrelvir 150 mg 
tablets and 1 bottle of ritonavir capsules at the Day 1 site visit. Participants will be instructed 
to take:
2 tablets of nirmatrelvir 150 mg or placeb o for nirmatrelvir q12h;
1 capsule of ritonavir 100 mg q12h.
oParticipants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 
m2[or eCrCl ≥30 to <60 mL/min] at screening) will receive either 1 tablet of 
nirmatrelvir 150 mg and placebo for nirmatre lvir or 2 tablets of placebo for 
nirmatrelvir. The dose for ritonavir remains unchanged (ie, participants will 
receive 1 capsule of ritonavir 100 mg q12h).
Participants should take the first dose of stud y intervention on Day  1, during the in- person 
visit; that is, participants should take nirmatrelvir/placebo and ritonavir at the same time (no 
more than 15 minutes apart). The study  intervention should be taken every 12 hours 
(±4hours), and not more than twice in a calendar day . Depending on the time of fir st dose, 
the timing of the second dose may  be adjusted slightl y to allow the participant/caregiver to 
select a convenient 12 hour dosing schedule as long as the next dose is taken at least 4 hours, 
but no later than 16 hours, after the first dose. Once the dosing schedule is adjusted, all 
subsequent doses should be taken every  12 hours (±4 hours).
If a dose is delay ed, it should be taken as soon as possible (but no later than 8 hours after the 
scheduled 12- hourly  dose time), then resume the normal dosing sc hedule. If the participant 
misses a dose by  more than 8 hours, the participant should not take the missed dose and 
instead take the next dose at the regularl y scheduled time. The participant should not double 
the dose to make up for a missed dose. Dosing should be stopped at the end of the treatment 
period (Day  5 or 6). Any  remaining tablets and/or capsules at the Day  5 visit should be 
returned. If the Day  5 visit is conducted prior to the last dose of stud y intervention (ie. 
Day 6), an y remaining tablets o r capsules should be collected at the next visit.
Participants will swallow the study  intervention whole and will not manipulate or chew the 
study  intervention prior to swallowing. Participants may  take the study  intervention with or 
without food. Taking study  intervention with food may  improve tolerability. Refer to the 
IPM for additional dosing and administration instructions.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 486.2.Preparation, Handling, Storage, and Accountability
The excipients used in the nirmatrelvir tablets/ritonavir capsules are safe for administration to 
pediatric participants.
Study  intervention will be self -administered or administered to the participant by  the 
caregiver. 
1.The investigator or designee must confirm that appropriate conditions (eg, temperature) 
have been maintained during transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/or administer study  intervention. 
3.All study  interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a minimum, 
daily  minimum and maximum temperatures for all site storage locations must be 
documented and ava ilable upon request. Data for nonworking day s must indicate the 
minimum and maximum temperatures since previously  documented upon return to 
business.
4.Any excursions from the study  intervention label storage conditions should be reported to 
Pfizer upon disc overy  along with actions taken. The site should activel y pursue options 
for returning the stud y intervention to labeled storage conditions, as soon as possible. 
Once an excursion is identified, the study intervention must be quarantined and not used 
until Pfizer provides permission to use the study  intervention. Specific details regarding 
the excursion definition and information to report for each excursion will be provided to 
the site in the I PM.
5.Any storage conditions stated in the SRSD will be superseded by the storage conditions 
stated on the label. Site staff will instruct participants on the proper storage requirements 
for take -home study  intervention.
6.Study  interventions should be stored in their original containers.
7.The investigator, institution, hea d of the medical institution (where applicable), or 
authorized site staff is responsible for study  intervention accountability , reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records), such as 
the IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a study intervention accountability form/record. All study  intervention containers
that is taken home by  the participant, both used and unused, must be returned to the 
investigator b y the participant. Returned study intervention must not be redispensed 
to the participants.
8.Further guidance and information for the final disposition of unused study  interventions 
are provided in the I PM. All destruction must be adequatel y documented. If destruction is 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 49authorized to take place at the investigator site, the investigator must ensure that the 
materials are destro yed in compliance with applicable environmental regulations, 
institutional policy , and any  special instructions provided by  Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day  of 
discovery as described in the I PM.
6.2.1. Preparation and Dispensing
A qualified staff member will dispense nirmatrelvir/ritonavir using unique container numbers 
via an IRT s ystem in the bottles and blister cards provided, according to the SoA. A second 
staff member will verify  the dispensing. The participant/caregiver should be instructed to 
maintain the product in the bottle and blister cards, as approp riate provided throughout the 
course of dosing and return the bottle and blister cards, as appropriate to the site at the next 
study  visit.
6.3.Assignment to Study Intervention
Allocation of participants to treatment groups will proceed through the use of an I RT s ystem. 
The site personnel (stud y coordinator or specified designee) will be required to enter or select 
information including but not limited to the user’s ID and password, the protocol number, 
and the participant number. The site personnel will then be provided with a randomization 
number corresponding to the assigned treatment group, and DU or container number(s) when 
study  intervention is being supplied via the IRT system. The I RT s ystem will provide a 
confirmation report containing the participant n umber, randomization number, and DU or 
container number assigned. The confirmation report must be stored in the site’s files. 
Study  intervention will be dispensed at the study  visits summarized in the SoA. 
The study -specific I RT reference manual and IPM will provide the contact information and 
further details on the use of the I RT sy stem.
6.4.Blinding
This is a double -blind study . 
6.4.1. Blinding of Participants
Participants and their caregivers will be blinded to their assigned study  inter vention.
6.4.2. Blinding of Site Personnel
Investigators and other site staff will be blinded to participants’ assigned study  intervention. 
Participants will be assigned to receive stud y intervention according to the assigned treatment 
group from the randomizati on scheme. Investigators will remain blinded to each participant’s 
assigned stud y intervention throughout the course of the study. 
In the event of a Qualit y Assurance audit, the auditor(s) will be allowed access to unblinded 
study  intervention records at the site(s) to verify  that randomization/dispensing has been done 
accuratel y.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 506.4.3. Blinding of the Sponsor
Sponsor staff will be blinded to participants’ assigned study  intervention, except for 
designated individuals who may conduct unblinded reviews of the dat a if requested by  
regulatory  authorities. An unblinded submissions team may  be assembled to prepare 
unblinded anal yses and documents to support regulatory  activities that may  be required while 
the study  is ongoing.
Sponsor staff who are not directly  involv ed with the conduct of this study  will prepare 
analyses and documentation containing unblinded data while the study  is ongoing to support 
interactions with the E -DMC.
The study  will be unblinded after all participants complete the Day 34 visit (or ET prior to 
Day 34 visit) and anal yses through Day  34, including the primary  efficacy  endpoint analy ses, 
will be conducted.
Details of the unblinded sponsor staff supporting the data review(s) described above and the 
timing of unblinding will be outlined in the Unblinding Plan.
6.4.4. Breaking the Blind 
The I RT will be programmed with blind -breaking instructions. I n case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Partic ipant safety  must alway s be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact the study  medical monitor prior to 
unblinding a participant’s treatment assignment unless this could delay  further management 
of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be 
notified within 24 hours after breaking the blind. The date and reason that the blind was 
broken must be recorded in the source documentation and CRF.
The study  specific IRT reference manual and IPM will provide the contact information and 
further details on the use of the I RT sy stem.
6.5. Study Intervention Compliance
Participants will use a participant -completed electronic dosing diary  to record the date and 
time of their study  intervention dosing, and will be educated at the time of first dose.
Site personnel will review the participant -completed electronic dosing diary  daily during the 
study intervention period, preferabl y after the participant has self -administered the morning 
dose of nirmatrelvir/ritonavir. If an y noncompliance with dosing is suspected, site personnel 
will promptly  contact the participant by  phone, to remind them of the re levant study  
procedures and/or entering the information in the electronic diary  as applicable.
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The dose of study  intervention and study  
participant identification will be confirmed at the time of dosing b y a member of the stud y 
site staff other than the person administering the study  intervention. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 51When participants self -administer study  intervention(s) at home , compliance with study  
intervention will be assessed at each visit. Compliance will be assessed b y delegated stud y 
personnel upon return of study  intervention through counting returned tablets/capsules and 
direct questioning, if applicable during the site visits and documented in the source 
documents. 
A record of the number of nirmatrelvir tablets/ritonavir capsules dispensed to and taken by  
each participant must be maintained and reconciled with study  intervention and compliance 
records.
The following no ncompliance cases will be considered medication errors (see Section 6.5):
Participants interrupting study  intervention for 2 consecutive doses;
Participants taking
either nirmatrelvir or ritonavir alone for 2 consecutive doses;
Participants who have an overall study intervention compliance <80% or >115%.
In addition to the above listed -medication errors, any  deviation from protocol -specified 
dosing (eg, missed single dose or partial dose) should be recorded as a protocol deviation and 
the investigator or designee is to counsel the participant/guardian and ensure steps are taken 
to improve compliance.
6.6.Dose Modification 
Not applicable.
6.7.Continued Access to Study I ntervention After the End of the Study
No study  intervention will be provided to participants at the end of their study  participation. 
It is expected that participants will be treated as required with standard -of-care treatments, as 
advised b y their usual care phy sician.
6.8.Treatment of Overdose
Study  sites should warn parents/caregivers to store the study  intervention out of reach of 
children and to provide close supervision when intervention will be self -administered by  the 
child.
For this study , any  dose of nirmatrelvir greater than 900 mg (or any dose greater than 450 mg 
for participants on the reduced nirmatrelvir dose for moderate renal impairment) or ritonavir 
greater than 300 mg within a 24 -hour time period will be considered an overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact the study  medical monitor within 24 hours.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 52Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities as 
medically  appropriate and at least until the next scheduled follow -up. 
2.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
3.Overdose is reportable to Pfizer Safety  only when associated with an SAE.
Decisions regarding dose interruptions or modificatio ns will be made by  the investigator in 
consultation with the study  medical monitor as needed based on the clinical evaluation of the 
participant.   
6.9.
Prior and Concomitant Therapy 
Permitted During the Study
Concomitant medications are permitted unless speci ficall y listed as prohibited medication 
(see Appendix 8 ) or as defined in Section 5.2. However, as described below, use of other 
specific COVID -19 treatments (eg, antivirals or monoclonal antibodies) are prohibited during 
the study .
Sites should consult with the sponsor if 
a new SoC option for COVID- 19 becomes available 
after stud y initiation. The I nvestigator should ensure that any  concomitant therap y is not a 
strong inducer of CYP3A4 or highl y dependent on CYP3A4 for clearance. The Pfizer 
medical monitor should be consulte d to review for potential drug -drug interactions (see 
Appendix 8 ).
Ritonavir is an inhibitor of CYP3A4 and may  increase plasma concentrations of drugs that 
are primarily  metabolized by  CYP3A4. Participants will re ceive ritonavir for 5 day s but as 
treatment is blinded, some concomitant medications ( Appendix 8, Table 4) may  requir e 
monitoring of drug levels, consideration of temporary withdrawal of the concomitant 
medication, or dose adjustment throughout the study  treatment period and following 
completion of the blinded treatment duration period.
Prohibited During the Study
Partic ipants are prohibited from receiving a non -study  COVID -19 antiviral or monoclonal 
antibody  therapy  for COVID
-19 within 14 day s prior to randomization (excluding qualify ing 
treatment with nirmatrelvir/ritonavir) and through completion of Day  34. Vaccination for 
COVID -19 is also prohibited within 14 day s prior to randomization and through completion 
of Day  34. 
As an exception, participants who progress to severe or critical COVID -19 will, however, be 
permitted to receive specific COVID -19 treatment(s) such a s antiviral therapy  or use of other 
treatments considered standard of care and the above restriction would not apply .
Nirmatrelvir and ritonavir are both primarily  metabolized by  CYP3A4. In addition, ritonavir 
is a strong inhibitor of CYP3A4. Therefore, co ncomitant use of medications that are strong 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 53inducers of CYP3A4 and which are contraindicated in combination with 
nirmatrelvir/ritonavir (see Appendix 8 Table 3) are prohibited during study treatment. Some 
medications that are highly  dependent on CYP3A4 for clearance are also contraindicated 
with nirmatrelvir/ritonavir (see Appendix 8 , Table 3).
Some other medications that are not contraindicated but are highly dependent on CYP3A4 
for clearance may  require dose adjustment or additional monitoring. Refer to Appendix 8
Table 4 for a nonexhaustive list of these medications and consult the Pfizer medical monitor 
for guidan
ce on coadministration with nirmatrelvir/ritonavir.
Medications or substances that are strong inducers of CYP3A4 and that are contraindicated 
in combination with nirmatrelvir/ritonavir must be discontinued for an appropriate washout 
period prior to the fir st dose of nirmatrelvir/ritonavir and are prohibited for the duration of 
the study  treatment period and for 4 day s after the last dose of nirmatrelvir/ritonavir 
(Appendix 8 ). The appropriate washout period for CYP 3A4 inducers should be determined 
based on the prescribing information for the concomitant medication and in consultation with 
the medical monitor.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention. Reasons 
for permanent discontinuation of study  intervention include the following:
AE of Grade 3 severity or greater and considered by the investigator to be related to 
study  intervention;
SAE considered b y the investigator to be related to study intervention;
Requirement for prohibited concomitant medication;
Study  terminated by  sponsor;
Withdrawal by  participant or legally  authorized representative;
If postsc reening eGFR is <30 mL /min/1.73 m2 (adult participants) or eCrCl is 
<30mL/min (adolescent participants), the participant will be instructed to 
discontinue any  remaining study  intervention doses as soon as study  staff become 
aware of the eGFR results.
In the event that a participant is hospitalized, study  intervention may  continue to be 
administered, as feasible, and based on medical judgment of the investigator.
Note that discontinuation of study  intervention does not represent withdrawal from the study . 
If study  intervention is permanentl y discontinued, the participant should remain in the study 
to be evaluated for all subsequent scheduled assessments . See the SoA for data to be 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 54collected at the time of discontinuation of study  intervention and follow -up for any  further 
evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -
up, 
and/or future collection of additional information.
7.1.1. Pregnancy 
For further details, refer to Section 8.4.5.1.
7.2.Participant Discontinuation/Withdrawal From the Study 
A participant may  withdraw from the study  at an y time at their own request. Reasons for 
discontinuation from the study
 include the f ollowing: 
Refused further stud y procedures;
Lost to follow up; 
Study  terminated by  sponsor;
Withdrawal of consent/assent by  parent/legal guardian or by  a child who has provided 
assent during an y phase of the study.
At the time of discontinuing from the s tudy (if prior to Day  34), if possible, an earl y 
discontinuation visit should be conducted. See the SoA for assessments to be collected at the 
time of study  discontinuation and follow -up and for an y further evaluations that need to b e 
completed. 
The early discontinuation visit applies only  to participants who are enrolled/randomized and 
then are prematurely  withdrawn from the study . Participants should be questioned regarding 
their reason for withdrawal.  
If a participant withdraws from the study , they  may  request destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and a lso withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use an y data 
collected before such withdrawal of consent.
7.2.1.
Withdrawal of Consent 
Participants who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent/assent for an y further 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 55contact with them or persons previously  authorized by  the participant to provide this 
information. Participants should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator , as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead ) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Follow -Up 
A participant will be considered lost to follow -up if the participant repeatedly  fails to return 
for scheduled visits and is unable to be contacted by  the study  site.
The following actions must be taken if a participant fails to be available for a required stud y 
visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned visit schedule, and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a participant is deemed lost to follow
-up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record;
Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the study . 
In the event the participant is deemed unreachable, the investigator should utilize the 
contact information collected for the 2 individuals who can be contacted if the 
participant cannot be reached after multiple attempts.
8.STUDY ASSESSMENTS AN
D PROCEDURES
8.1.Administrative and Baseline Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allow ed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 56All screening evaluations must be completed and reviewed to confirm that potential 
participants meet a ll eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every ef fort should be made to ensure that protocol -required tests and procedures are 
completed as described. However , it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that they  have taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner .
In the event a participant is hospitalized, study  assessments should be performed as feasible. 
Procedures not perf ormed due to hospitalizations will not be considered protocol deviations.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participants in this study  is approximately  
160 mL . The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times sp ecified b y Pfizer, provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 56 consecutive 
days. For pediatric participants, every  effort will be made to ensure that blood volume 
collections do not exceed 1% of the total blood volume at an y single time and 3% of the total 
blood volume during an y period of 4 weeks.
8.1.1. Baseline Procedures
8.1.1.1. Medical History
Medical history , COVID -19 disease history  and SARS -CoV -2 tests results if available, and 
demographics will be collected at s creening. Smoking status will be collected. Complete 
medication history  of all prescription or nonprescription drugs (including vaccinations), and 
dietary  and herbal supplements taken within 30 day s prior to the planned first dose will be 
collected. COVID -19 vaccinations, antiviral and monoclonal antibody  treatment for the 
treatment of COVID -19 at any  time prior to the planned first dose will also be collected.
Risk factors for the participant developing severe COVID- 19 illness will be recorded.
8.1.1.2. Secondary C ontacts
At baseline and as noted in the SoA, the investigator will collect contact information for at 
least 2 individuals who can be contacted if the participant cannot be reached after multiple 
attempts. Secondary  contacts may  be us ed to determine if a participant is lost to follow -up or 
vital status check.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 578.1.2. Household Characteristics
Household characteristics will be determined through interview with the study  participant 
and will be updated during the stud y. The household characteris tics include:
Number of people living in household;
Number of additional confirmed SARS -CoV -2 positive or suspected (ie, 
symptomatic) household members and date of confirmed or suspected SARS -CoV -2.
8.1.3. Telehealth Visits
Telehealth visits may  be used to assess participant safet y and collect data points. Telehealth 
includes the exchange of healthcare information and services via telecommunication 
technologies (eg, audio, video, videoconferencing software) remotel y, allowing the 
participant and the investigator to communicate on aspects of clinical care, including medical 
advice, reminders, education, and safet y monitoring. The following assessments must be 
performed during a telehealth visit (see the SoA):
Review and record stud y intervention(s), including compliance and missed doses.
Review and record an y AEs and SAEs since the last contact. Refer to Section 8.4.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Review and record contraceptive method and results of pregnancy testing. Confirm 
that the participant is ad hering to the contraception method(s) required in the 
protocol. Refer to Appendix 4 .
Study  participants must be reminded to promptl ynotify site staff about an y change in their 
health status.
Observe (ie, vide o, videoconferencing software) the participant performing the rapid antigen 
test (participant self collected rapid antigen test), if the procedure is conducted remotel y, and 
record the results for offsite visits in accordance with the SoA .
8.1.4. Home Health Visits 
A home health visit may beutilized to facilitate scheduled visits. Home health visits include 
a healthcare provider conducting an in -person study  visit at the participant’s location, rather 
than an in -person stud y visit at the s ite. The following may be performed during a home 
health visit (see the SoA):
Review and record stud y intervention(s), including compliance and missed doses.
Review and record an y AEs and SAEs since the last contact. Refer to Section 8.4.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 58Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Revie w and record contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the 
protocol. Refer to Appendix 4 .
Collect clinical labora tory and biomarker samples.
Observe rapid antigen testing, record result, and collect NP/OP swab samples.
Collect vital signs.
Confirm the participant has completed the PRO assessments.
Retrieve unused stud y intervention and empt y study intervention contai ners
Collect/update secondary contacts
Collect/update household characteristics
Collect COVID -19-related medical visits
Collect COVID -19 adjunctive therapeutic procedures
If the HCP is unable to collect AEs, concomitant medications, the site should contact
the participant via a follow
-up telephone call to collect the additional information.
It is recommended that the investigator discuss temporary  or permanent discontinuation of 
study  intervention with the study  medical monitor.
8.2.Efficacy Assessments
8.2.1. Partici pant Diary
Participants will be provided an electronic handheld device or will use their own device to 
record stud y intervention administration, signs and symptoms of COVID -19, and PRO 
assessments in the study  diary . 
Participants will receive daily  reminders to complete entries on their own as specified in the 
SoA. The diary  should be completed at approximately  the same time every day . Staff will 
review the participant’s study  diary  online as spe cified in the SoA.
The diary  allows recording of these assessments only  within a fixed time window (next 
calendar day ), thus providing an accurate representation of the participant’s experience at 
that time. The participant is able to make revisions to incorrect entries before pressing the 
save or submit button. I n the event that a participant becomes aware of an error in data after 
the entry  is saved, a change to the diary  data may  only  be made by  the investigator 
submitting a data c larification form. Data reported in the participant diary  will be transferred 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 59electronically  to a third- party  vendor, where they  will be available for review by  investigators 
and the sponsor or delegate at all times via an internet-based portal.
8.2.2. COVID -19-Related Medical Details
Details of participants’ COVID -19-related medical visits will be collected. These are 
hospitalization of any duration, urgent care, emergency  room ≤24h, practitioner’s office, 
telemedicine, home health care services or exte nded care facility  stay and will be collected 
during stud y visits, including level of care (I CU status) and dates of utilization, including 
admission and discharge, as applicable. 
Hospitalization >24 hours is defined as >24h of acute care in a hospital or similar acute care 
facility , including Emergency  Rooms or temporary  facilities instituted to address medical 
needs of those with severe COVID -19. This includes specialized acute medical care unit 
within an assisted living facility  or nursing home. This does not include hospitalization for 
the purposes of public health and/or clinical trial execution.
8.2.3. PRO Assessments
PRO assessments will be recorded in the study  eDiary .
8.2.3.1. Global Impression Questions
Three questions will be included in the ePRO to assess patie nt-reported global impression 
items: a) return to usual health; b) return to usual activities; and c) overall COVID -19-related 
symptoms [17]. For participants who report COVID -19 sy mptoms in the diary , the global 
impression questions will be answered after the completion of the COVID -19 signs and 
symptoms diary  is completed.
8.2.3.2. SF-
36 v2®Health Survey (Acute Form)[ 18]
Only  adult study  participant s ≥18 y ears of age at the time of screening will be asked to 
complete the SF -36 at the timepoints indicated in the SoA. 
SF-
36 v2®Health Survey (the acute form) is a 36- item questionnaire that measures 
functional health and well -being from a patient’s perspective over a 1 -week recall period. It 
is a generic questionnaire and can be used across age (adults), disease, and treatment groups. 
The questionnaire consists of 8 health domain scales: phy sical functioning (10 items), role 
physical (4 items), bodily pain (2 items), general health (5 items), vitality  (4 items), social 
functioning (2 items), role -emotional (3 items), mental health (5 items), reported health 
transition (1 item) and 2, physical and mental component summary  scores. Ea ch health 
domain scale raw score is transformed to 0 -100 scale which can then be converted to norm 
based T- scores (Mean=50, SD=10). SF -36 v2®Health Survey  will be completed as specified 
in the SoA .
8.2.3.3. WPAI
Only  adult study  participants ≥18 y ears of age at the time of screening will be asked to 
complete the WPAI  at the timepoints indicated in the SoA.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 60COVID -19 impacts manual and office -based work, and results in missed work due to illness 
or quarantine and loss of productivity  [19]. The WPAI -GH is being implemented for COVID 
19 (ie, WPAI -COVID -
19) in order to evaluate change from baseline in work burdens. The 
WPAI -GH has demonstrated validity , reliability  and sufficient predictive value to measure 
the impact of disease on absenteeism, presenteeism, and overall productivity  in a manner that 
can also be monetized [20].
The WPAI -COVID -19 consists of 6 questions that refer to the following assessments for 
work productivity : 1 = currentl y emplo yed, 2 = hours missed due to health problems, 3 = 
hours mis sed for other reasons, 4 = hours actually  worked, 5 = degree health affected 
productivity  while working (using a 0 to 10 VAS), and 6 = degree health affected 
productivity  in regular unpaid activities.    The recall period for questions 2 through 6 is 7 
days. Four main outcomes will be generated from the WPAI -COVID -
19 and reported as: 1) 
percent work time missed due to COVID -19 for those who are currentl y employ ed, 2) 
percent impairment while working due to COVID -19 for those who are currently  employ ed 
and a ctuall y worked in the past 7 days, 3) percent overall work impairment due to COVID -19 
for those who are currently  employ ed, and 4) percent activity  impairment due to COVID -19 
for all respondents [20]. The WPAI -COVID -19 will be completed as specified in the SoA.
8.2.3.4. EQ-
5D-5L Scale
Only  adult study  participants ≥18 y ears of age at the time of screening will be asked to 
complete the EQ -5D-5L at the timepoints indicated in the SoA.
The EQ -5D is a validated, standardized, generic instrument that is a preference-ba sed health 
related qualit y of life questionnaire in cost effectiveness and HTA [21-23] . Recently, a 
version was developed called EQ -
5D-5L with 5 response levels on each dimen sion compared 
to the 3 response levels in the EQ -5D- 3L[21-27].
Measure ment properties of the EQ -
5D-5L demonstrated to be a valid version of the 3 level 
questionnaire that improved measurements by  adding discriminatory  power, reducing the 
ceiling, and establishing convergent and known groups validity [21,23,25,26 ]. Both the 
EuroQol EQ -
5D-3L and EQ -5D- 5L versions are well established instruments used to 
measure health states and utilities in various diseases areas and assess mobility , self -care, 
usual activities, pain/discomfort, anxiety /depression and health status using a VAS [24,28]. 
The EQ -
5D-5L should be completed as described in the SoA.
8.2.3.5. COVID -19 Signs and Symptoms
On Day  1, participants wi ll complete the COVID -19 signs and s ymptoms ( Appendix 11) in 
the study  diary , before receiving stud y intervention. Participant assessment of COVID -19-
related s ymptoms should be recorded at approximately the same time each day  as specified in 
the SoA and as described in Appendix 11.
COVID -19-related s ymptoms will be evaluated in accordance with FDA guidelines. 
Participants will r ecord a rating of their s ymptom severit y over the past 24 hours based on a 
4-point scale in which 0 is reported if no s ymptoms were present; 1 if mild; 2 if moderate; 
and 3 if severe. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 61Vomiting and diarrhea will each be rated on a 4 -point frequency  scale where 0 is reported for 
no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater.
Sense of smell and sense of taste will each be rated on a 3- point L ikert scale where 0 is 
reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was 
less than usual, and 2 for no sense of smell/taste.
During the long -term follow -up period as noted in the SoA , site staff will ask participants if 
they have experienced pre -defined COVID -19 signs and sy mptoms or other sy mptoms 
believed to be related to COVID
-19, over the past 7 day s, including the day  of the study  visit. 
For each sign or s ymptom reported, the worst severity  (mild, moderate or severe) during the 
past week should be recorded in the CRF.  
8.3. S afety Assessments
Planned time points for all safety  assessments are provided in the SoA. Unscheduled safet y 
measurements may  be obtained at any  time during the study  to assess any  perceived safety  
issues.
8.3.1. Targeted Physical Examination, Height and Weight
Physical examination is to be completed before administration of study  intervention.
A targeted ph ysical examination will include, at a minimum, cardiopulmonary  assessments.  
Height and weight will also be measured and record ed at screening, though height may  be 
self-reported for participants ≥18 y ears of age .
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to th e processes in
Sections 8.4.1 to 8.4.3.
8.3.2. Vital Signs
Temperature, p ulse rate, respiratory  rate, oxy gen saturation level, and blood pressure will be 
assessed as specified in the SoA.
Any untoward vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 
8.4.1 to8.4.3 .
8.3.2.1. Blood Pressure and Pulse Rate
BP and PR measurements will be assessed with the participant, preferabl y in the seated 
position with their fee t on the floor when possible with a completel y automated device [29]. I t 
is recommended that the same position should be used for a participant throughout the stud y 
duration. Manual techniques will be used only  if an automated device is not available.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 628.3.2.2. Temperature and Respiratory Rate
Temperature and respirat ory rate will be assessed .
8.3.2.3. Oxygen Saturation Level
Oxygen saturation level will be assessed as part of the vital signs assessment.
8.3.2.4. Point -of-Care Serum Creatinine Assessments
A serum creatinine point -of-care device will be used to assess kidney  function as described in 
the SoA and Appendix 7 . If a serum creatinine point -of-care device assessment is performed 
at screening and baseline, the baseline estimate of kidney function will determine eligibility.
8.3.3. Clinical Safety Laboratory Assessments 
Laboratory  safet y parameters will be graded according to the DAIDS Table for Grading the 
Severity  of Adult and Pediatric Adverse Events
[30], version 2.1. See Appendix 2 for the list 
of clinical safety  laboratory  tests to be performed and the SoA for the timing and frequency . 
All protocol -required laboratory  assessments, as defined in Appendix 2 , must be conducted 
in accordance with the laboratory  manual and the SoA. Unscheduled clinical laboratory  
measurements may  be obtained at any  time during the study  to assess any  perceived safety  
issues.  
The investigator must review the laboratory  report, document this review , and record an y 
clinically  significant changes occurring during the study  in the AE section of the CRF .
Clinically  significant abnormal laboratory  test finding s are those that are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significant and abnormal during 
participation in the study  or within 28 day safter the last dose of stud y intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or stud
y medical monitor .
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator , the etiology  should be identified and the sponsor notified.
See Appendix 6 for suggested actions and follow -up assessme nts in the event of potential 
DILI.
See Appendix 7 for instructions for laboratory  testing to monitor kidney  function and 
reporting laboratory  test abnormalities.
8.3.3.1. Alternative Facilities for Clinical Safety Laboratory Ass essment 
If a local laboratory  is used, qualified stud y site personnel must order, receive, and review 
results. Site staff must collect thelocal laboratory  reference ranges and certifications/
accreditations for filing at the site. Laboratory test results are to be provided to the site staff 
as soon as possible . The local laboratory  reports should be  filed in the participant’s source 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 63documents/medical records. Relevant data from the local laboratory  report should 
be recorded on the CRF.
8.3.4. Pregnancy Testing
Aserum or urine pregnancy  test is required at screening. Following screening, pregnancy  
tests may  be urine or serum tests, and must have a sensitivity  of at least 25 mIU/mL. 
Pregnancy  tests will be performed in WOCBP at the times listed in the SoA . Pregnancy  tests 
will also be done whenever 1 menstrual cycle is missed during the active treatment period (or 
when potential pregnancy is otherwise suspected) and at Day  34 or the ET visit. Pregnancy  
tests may  also be repeated if requested by IRBs/ECs or if required by  local regulations. If a 
urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy  test 
is required. In such cases, the participant must be excluded if the serum pregnancy  result is 
positive.
For a female pediatric participant who becomes pregnant, this information will be shared 
with the study  participant’s parent/guardian if the participant’s age is within the specific 
range based on local/country  regulations.
8.3.4.1. At Home Pregnancy Testing
If a partic ipant requiring pregnancy  testing cannot visit a local laboratory , a home urine 
pregnancy  testing kit with a sensitivity  of at least 25 mI U/mL may  be used by  the participant 
to perform the test at home, if compliant with local regulatory  requirements. The pregnancy  
test outcome should be documented in the participant’s source documents/medical records 
and relevant data recorded on the CRF. Confirm that the participant is adhering to the 
contraception method(s) required in the protocol.
8.4.Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or , when appropriate, by  a caregiver , surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the investigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event mee ts the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1). 
During the active collection period as described in 
Section 8.4.1, each 
participant /caregiver/parent/legal guardian/legally authorized re presentative will be 
questioned about the occurrence of AEs in a nonleading manner .
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -up 
information in an expedited fashion.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 648.4.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“ active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before undergoing an y stud y-related procedure and/or receiving study  
intervention, through and including a minimum of 28 calendar day s, except as indicated 
below, after the last administration of the study  intervention. 
Follow -up by  the investigator continues throughout the active collection period and until the 
AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator .
When a clinically  important AE remains ongoing at the end of the active collection period, 
follow -up by  the investigator continues until the A E or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the pa rticipant withdraws from the study  and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently  discontinues or temporaril y discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the PSSA. 
Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has concluded study  participation. However, if the in vestigator learns of any  SAE, 
including a death, at an y time after a participant has completed the stud y, and they consider 
the event to be reasonably related to the stud y intervention, the investigator must promptly  
report the SAE to Pfizer using the PSSA
.
8.4.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.4.1 are repor ted to Pfizer Safety  using the PSSA immediately  upon awareness and 
under no circumstance should this exceed 24 hours, as indicated in Appendix 3 . The 
investigator will submit any  updated SAE data to the s ponsor within 24 hours of its being 
available.
8.4.1.2.
Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.1 , will be recorded 
on the AE section of the CRF .  
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 65As part of ongoing safet y rev iews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE. To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to pr ovide clarity  and understanding of the event in the context of the clinical 
study .
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open
-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.4.3. Follow -Upof AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabiliza tion, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in suf ficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and i llnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is provided in Appendix 3 .
8.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clin ical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for SUSARs according to local regu latory  
requirements and sponsor policy  and forwarded to investigators as necessary .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 66An investigator who receives SUSARs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study
 intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, an d others who may be exposed. An 
environmental exposure may  include EDP , EDB, and occupational exposure.
Any such exposures to the study  intervention under study  are reportable to Pfizer Safety  
within 24 hours of investigator awareness.
8.4.5.1. Exposure During Preg nancy
An EDP  occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention. 
A male participant who is receiving or has discontinued study  intervention 
inseminates a female partner. 
A female nonparticip ant is found to be pregnant while being exposed or having been 
exposed to study  intervention because of environmental exposure. Below are 
examples of environmental EDP:  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  ingestion.
A male famil y member or healthcare provider who has been exposed to the study 
intervention by  ingestion then inseminates his female partner prior to or around 
the time of conception.
The investigator must report EDP  to Pfizer Safety within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
terminati on of pregnancy). 
If EDP occurs in a participant/participant’s partner, the investigator must report this 
information to Pfizer Safety  using the EDP Supplemental Form within PSSA, 
regardless of whether an SAE has occurred. Details of the pregnancy  will be collected 
after the start of stud y intervention and until a minimum of 28 calendar days after the 
last administration of study intervention. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 67If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety using the PSSA. Since the exposure information does not 
pertain to the participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed PSSA case report form is maintained in the 
investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up using PSSA. In the case of a live birth, the structural integrit y of the neonate can 
be assessed at the time of birth. I n the event of a termination, the reason(s) for termination 
should be specified and, if clinically  possible, the structu ral integrit y of the terminated fetus 
should be assessed b y gross visual inspection (unless preprocedure test findings are 
conclusive for a congenital anomal y and the findings are reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death ), the in vestigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion should be reported 
as an SAE;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to
exposure to the study  intervention. 
Additional information regarding the EDP  may  be requested by  the sponsor . Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Preg nant Partner Release of Information Form to provide to his 
partner .
8.4.5.2. Exposure During Breastfeeding
An EDB occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study  intervention (ie, environmental exposure). An example of 
environmental EDB is a female famil y member or healthcare provider who reports 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 68that she is bre astfeeding after having been exposed to the study  intervention by  
ingestion.  
The investigator must report EDB to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the PSSA. When EDB occurs in the setting of environmental exposure, the exposure 
information does not pertain to the participant enrolled in the study , so the information is not 
recorded on a CRF. However, a cop y of the completed SAE Case Report form from PSSA is 
maintained in the investigator site file.
An EDB report is not created when a Pfizer drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. 
However , if the infant experience s an SAE associated with such a drug, the SAE is reported 
together with the EDB.
8.4.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 24 
hours of the investigator’s awareness using the PSSA, regardless of whether there is an 
associated SAE. Since the information about the occupational exposure does not pertain to a 
participant enrolled in the study, the information is not recorded on a CRF; however, a copy  
of the completed SAE Case Report form from PSSA must be maintained in the investigator 
site file.
8.4.6. Cardiovascular and Death Events
Not applicable.
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
Not applicable. 
8.4.8.1. Lack of Efficacy
The investigator must report signs, s ymptoms, and/or clinical sequelae resulting from lack of 
efficac y. Lack of ef ficacy or failure of expected pharmacological action is reportable to Pfizer 
Safety  only if associated with an SAE .  
8.4.9.
Medical Device Deficiencies
Not applicable.
8.4.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by  the wrong participant, or at the wrong time, or at the wrong dosage strength.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 69Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported using the PSSA 
to Pfizer Safety Within 24 
Hours of Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly  if associated with an 
SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
The administration of expired study  intervention;
The administration of an incorrect study  intervention;
The administration of an incorrect dosage;
The administration of study  intervention that has undergone temperature excursion 
from the specified storage range, unless it is determined by  the sponsor that the study  
intervention under question is acceptable for use.
The administration of study  intervention consistent with the medication error 
descriptions in Section 6.5.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF , which is a specific version of the AE page.
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator , the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associat ed AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
In the event of a medication dosing error , the sponsor should be notified within 24 hours.
Medication errors should be reported to Pfizer Safety within 24 hours using PSSA only when
associated with an SAE.
8.5.Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study . 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 708.6.Genetics
8.6.1. Specified Genetics
Specified genetic anal yses are not evaluated in this study .
8.6.2. Retained Research Samples for Genetics
A 4-mLblood sample optim ized for DNA  isolation Prep D1 will be collected according to 
the 
SoA, as local regulations and I RBs/ECs allow .
Retained Research Samples may  be used for research related to the study  intervention(s) and 
COVID -19. Genes and other an alytes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the retained samples. 
See Appendix 5for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the laboratory
 manual .
8.7.Biomarkers
Collection of samples for biomarker research is also part of this study . 
The following samples for biomarker research are required and will be collected from all 
participants in this study  as specified in the SoA:
Nasophary ngeal swab will be collected to assess SARS -CoV -2 viral RNA level.
A plasma sample will be collected to assess SARS- CoV -2 viral RNA level.
Orophary ngeal swab will be collected to assess SARS -CoV -2 viral RNA level
A plasma sample will be collected and may  be used for protein biomarker analy sis.
Retained research samples.
8.7.1. Viral RNA Assessment (NP Swab)
An NP swab of both nares will be collected b y HC P as per the SoA from participants and 
will be anal yzed to measure SARS -CoV -2 RNA by  RT-PCR. At Screening and Baseline 
(Day  1) onl y, rapid antigen testing can be done before NP swab collection. At all other 
timepoints, NP swab collection must occur prior to any Rapid Anti gen Assessment . 
Residual samples may  be used for viral sequencing to assess for signs of viral evolution and 
evaluation of potential genetic viral variants, infectivity , phenot ypic assays, and additional 
molecular analy sis. Host genetic analy sis may  also b e performed. 
Residuals of all samples may  be stored for future research. Storage and shipping instructions 
will be in accordance with the laboratory  manual.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 718.7.2. Viral RNA Assessment (Plasma)
A 6-mL blood sample will be collected per the SoA from participants and may  be anal yzed to 
measure SARS -CoV -2 RNA by  RT-PCR. Residual samples may  be utilized for viral 
sequencing, infectivity  and phenoty pic assay s and additional molecular analy sis. Host genetic 
analysis may  also be performed. 
Residu als of all samples may
 be stored for future research. Storage and shipping instructions 
will be in accordance with the laboratory  manual.
8.7.3. Rapid Antigen Assessments
Rapid antigen testing for SARS -CoV -2 will be self- collected by  the participant as described 
in the SoA . Sites will use test kits that are authorized for use in this study . At Screening and 
Baseline (Day  1) only , rapid antigen testing can be done before NP swab collection. At all 
other time points, rapid antigen testing must be done after NP swab collection. When 
participants have 2 consecutive negative rapid antigen tests separated by  at least 24[ -2]h, 
rapid antigen testing will revert to on site rapid antigen testing as noted in the SoA.
Site staff should train participants /caregiver at the screening/baseline visit to ensure 
participants can perform the rapid antigen test appropriatel y. The participant should perform 
the baseline rapid antigen testing assessment during the visit to ensure proper sample 
collection under obser vation by  site staff.
8.7.4. Viral Sequencing Assessments (OP Swab)
An OP swab will be collected b y the HCP as per the 
SoA from participants may  be anal yzed 
to measure SARS -CoV -2 RNA by  RT-PCR. OP swabs should be obtained after NP swab 
collection and rapid antigen testing . Residual samples may  be utilized for viral sequencing, 
infectivity  and phenot ypic assays and additional molecular anal ysis. Host genetic analy sis 
may also be performed.
Residuals of all samples may  be stored for future res earch.  Storage and shipping instructions 
will be in accordance with the laboratory  manual.
8.7.5. Specified Gene Expression (RNA) Research
Specified gene expression (RNA) research is not included in this study .
8.7.6. Specified Protein Research 
8.7.6.1. Plasma for Protein Analysis
A 6-mL blood sample will be collected, as specified in the SoA, and isolated for plasma for 
biomarker anal ysis. Analy sis may  include but is not limited to proteomics and immunologic 
assessments. Residuals of all samples may  be stored and used for additional analy ses related 
to COVI D
-19 and/or the mechanism of action of nirmatrelvir/ritonavir.
Details on processes for collection and shipment of these sample(s) can be found in the 
laboratory  manual.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 728.7.7. Specified Metabolomic Research 
Specified metabolomic research is not included in this study .
8.7.8. Retained Research Samples for Biomarkers
These Retained Research Samples will be collected in this study :
4-mL whole blood Prep B2.5 optimized for serum
2.5-mL whole blood Prep R1 optimized for RNA;
15-mL urine Prep M3.
Retained Research Samples will be collected as local regulations and IRB/ECs allow 
according to the SoA.  
Retained Research Samples may  be used for research related to the study  intervention(s) and 
COVID -
19. Genes and other anal ytes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the retained samples. 
8.8.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.9.Health Economics
Health econom ics/medical resource utilization and health economics parameters will be 
evaluated in this study  (Section 8.2.2 and Section 
8.2.3).
9.STATISTICAL CONSIDER
ATIONS 
Detailed metho dology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in the SAP, which will be maintained by the sponsor. 
The SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.1.Statistical Hypothesis
The primary  hypothesis is to test whether or not there is a difference in mean change of viral 
RNA level in NP swabs from baseline to Day  5 between nirmatrelvir/ritonavir and the 
placebo/ritonavir group:
Null hy pothesis:  H 0                  /          −         /          = 0           
Alternative h ypothesis: H a                  /          −         /          ≠ 0          
Where µ nirmatrelvir/ritonavir and µ placebo/ritonavir are mean change of viral RNA level in NP swabs 
from baseline to Day  5 for nirmatrelvir/ritonavir and placebo/ritonavir groups.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 739.1.1. Estimands
9.1.1.1. Primary Estimand
The primary estimand is the difference in mean change of SARS -CoV -2 RNA level in NP 
swabs from baseline to Day  5 between nirmatrelvir/ritonavir and placebo/ritonavir group in 
patients with a rebound in COVID-19 s ymptoms and a positive rapid antigen test within 
2week s following completion of an initial 5 -day treatment course, who have a positive viral 
RNA NP swab test result at baseline. This will be estimated without regard to study  treatment 
discontinuation and without regard to prohibited therapies.
9.1.1.2. Secondary Estim ands
The secondary  estimands are:
The hazard ratio for time to 2 consecutive negative rapid antigen test results obtained 
at least 24 ( -2) h apart through Day  28 between nirmatrelvir/ritonavir and 
placebo/ritonavir group in patients with rebound in COVID -19 s ymptoms and a 
positive rapid antigen test within 2 weeks following completion of an initial 5- day 
treatment course, who have a positive viral RNA NP swab test result at baseline. This 
will be estimated without regard to stud y treatment discontinuation a nd without 
regard to prohibited therapies.
The hazard ratio for time to sustained alleviation of all targeted signs and s ymptoms 
through Day 28 between nirmatrelvir/ritonavir and placebo/ritonavir group in patients 
with rebound in COVID -19 sy mptoms and a p ositive rapid antigen test within 2 
weeks following completion of an initial 5
-day treatment course, who have a positive 
viral RNA NP swab test result at baseline. This will be estimated without regard to 
study  treatment discontinuation and without regard to prohibited therapies.
9.1.2. Multiplicity Adjustment
The overall Ty pe I error rate across the primary  and key  secondary  efficacy  endpoints will be 
controlled at alpha = 0.05. Following the positive test of the primary  efficacy  endpoint in the 
primary  anal ysis set (mITT), the secondary  anal ysis for the primary efficacy  endpoint using 
the mI TT1 anal ysis set will be tested.  
Following the positive test of the secondary  anal ysis, the following secondary efficacy 
endpoints will be tested using Hochberg method [31]:
Time to 2 consecutive negative rapid antigen test results obtained at least 24 ( -2)h 
apart through Day  28 in the mITT anal ysis set.
Time (day s) to sustained alleviation of all targeted signs and s ymptoms through 
Day 28 where sustained alleviation is defined as the first of two consecutive day s 
when an y symptoms scored as moderate or severe at baseline are sc ored as mild or 
absent and an y symptoms scored as mild or absent at baseline are scored as absent in 
the mI TT anal ysis set.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 749.2.Analysis Sets 
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Full anal ysis set (FAS) All participants randomly  assigned to study  intervention. 
Safety  anal ysis set (SAS) All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention. 
Participants will be anal yzed according t o the study  
intervention they  received.
mITT All participants randomly  assigned to study  intervention who 
take at least 1 dose of study  intervention and who have a 
positive viral RNA NP swab test result ( ≥2.0 log 10
copies/mL ) at baseline.
Participants will be anal yzed according to the study 
intervention they  were randomized.
mITT1 All participants randomly  assigned to study  intervention who 
take at least 1 dose of study  intervention and who have a 
positive rapid antigen test result at baseline.
Participants will be anal yzed according to the study 
intervention they  were randomized.
Per protocol(PP) All participants in the mITT anal ysis set without important 
protocol deviations considered to impact the interpretation of 
the primary  efficacy  endpoint. Protocol deviations will be 
reviewed to generate the list of participants with significant 
deviations to be excluded from the PP analy sis set. The PP 
exclusion criteria will be finalized prior to breaking the blind.
9.3. Statistical Analyses
The SAP will be d eveloped and finalized before analyses are performed and will describe the 
analyses and procedures for accounting for missing, unused, and spurious data. This section 
is a summary  of the planned statistical anal yses of the primary  and secondary  endpoints.
9.3.1. General Considerations
Baseline demographic and other characteristics will be tabulated for the FAS and 
summarized by  treatment group. Quantitative variables will be described by  standard 
descriptive statistics and qualitative variables will be summarized by  frequency  tables wit h 
number and proportion in each category . 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 75For continuous endpoints, an MMRM or ANCOVA model will be used to anal yze change 
from baseline, whichever is appropriate. Estimated mean differences between treatments 
groups will be calculated.
For categorical en dpoints, proportion of participants for each category  will be summarized 
for each group.
For count endpoints, the total number of the events and average number of events will be 
summarized for each group.
Time to event will be summarized graphicall y using Kaplan -Meier plots for each treatment 
group. Treatment comparisons will be conducted using log -rank test or Cox proportional 
hazard model as appropriate.
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis
9.3.2.1. Definition of Endpoint(s)
The primary  efficacy  endpoint is th e change in viral SARS- CoV -2 RNA level from baseline 
to Day  5 as measured in NP swabs.
9.3.2.2. Main Analytical Approach
The primary  anal ysis for mean change in SARS -CoV -2 RNA level from baseline will be 
performed using a MMRM. The anal ysis will include the fixed e ffects of treatment, 
geographic region, baseline viral RNA level, visit, and treatment -by-visit interaction. An 
unstructured (co)variance structure will be used to model the within -participant variability . 
The L S means and treatment difference for each vis it will be calculated and presented with 
their corresponding 95% CI s. The primary  comparison for treatment effect will be the 
difference in LS means and 95% CI  at Day  5. The primary  anal ysis will be performed using 
mITT anal ysis set.
The secondary  analy sisfor primary  endpoint will be performed using the mI TT1 anal ysis set.
9.3.3. Secondary Endpoints
9.3.3.1. Time to 2 consecutive negative rapid antigen test results obtained at least 24(-
2)h apart through Day 28
For the event of 2 consecutive negative rapid antigen test re sults obtained at least 24( -2)h 
apart through Day  28, the date of the first negative rapid antigen test result will be considered 
the First Event Date.
Time to 2 consecutive negative rapid antigen test results obtained at least 24( -2)h apart for 
the purpos e of this study  is defined as:
For a participant achieving the event, time to event will be calculated as (First Event 
Date) –(First Dose Date) +1.
For a participant not achieving the event (censored), censoring date will be at the last 
date of rapid anti gen test measurement, and time will be calculated as (Censoring 
Date) –(First Dose Date) +1 or Day  27 whichever occurs first (Day 27 is the last 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 76possible day  to achieve 2 consecutive negative rapid antigen test results obtained at 
least 24( -2)h apart thro ugh Day  28).
Cox proportional hazard model anal yses will be used for time to 2 consecutive negative rapid 
antigen test results obtained at least 24( -2)h apart in mI TT anal ysis set. Cox proportional 
hazard model will include treatment, geographic region and potential covariates as 
appropriate.  The treatment group comparison will be presented as the estimate of the hazard 
ratio, 95% CI and p -value. In addition, time to 2 consecutive negative rapid antigen test 
results obtained at least 24(-2)h apart will be summarized graphicall y using Kaplan- Meier 
plots for each of the treatment groups in mITT analy sis set. 
Similar analy ses for time to 2 consecutive negative rapid antigen test results obtained at least 
24(-2)h apart will also be performed in the m ITT1 anal ysis set.
9.3.3.2. Time (days) to sustained alleviation of all targeted signs and symptoms through 
Day 28
Sustained alleviation of all targeted COVID -19 signs/sy mptoms is defined as the event 
occurring on the first of 2 consecutive day s when all sy mptoms scored as m oderate or severe 
at study  entry  are scored as mild or absent AND all sy mptoms scored mild or absent at study  
entry  are scored as absent. The first day  of the 2 consecutive -day period will be considered 
the First Event Date.
For s ymptoms with no reported s everit y in baseline, the symptom will have to be absent in 
order to be counted as sustained alleviated (missing severit y at baseline will be treated as 
mild).
Day 27 is the last possible day  that s ymptom alleviation can be achieved (definition includes 
data from the subsequent day ) and Day  28 is the last day  participants report their daily  signs 
and sy mptoms.
The time to sustained symptom alleviation for the purpose of this study  is defined as:
For a participant with sustained sy mptom alleviation, time to e vent will be calculated 
as (First Event Date) –(First Dose Date) +1.
For a participant that either completes Day  28 of the study  or discontinues from the 
study  before Day  28 without sustained sy mptom alleviation(censored), censoring date 
will be at the la st date on which sy mptom alleviation is assessed, and time will be 
calculated as (Censoring Date) –(First Dose Date) +1 or Day  27 whichever occurs 
first.
Participants who are hospitalized for the treatment of COVID -19 or die from any  cause 
during the 28-day period will be classified as not achieving sustained sy mptom alleviation 
and will be censored at day  27.
Cox proportional hazard model anal yses will be used for time to sustained sy mptom 
alleviation in mI TT analy sis set. Cox proportional hazard mode l will include treatment, 
geographic region and potential covariates as appropriate.  The treatment group comparison 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 77will be presented as the estimate of the hazard ratio, 95% CI  and p -value. In addition, time to 
sustained sy mptom alleviation will be summa rized graphicall y using Kaplan- Meier plots for 
each of the treatment groups in mI TT anal ysis set.
Similar analy ses for time to sustained sy mptom alleviation will also be performed in the 
mITT1 anal ysis set.
9.3.4. Tertiary/Exploratory Endpoint(s) Analysis
Details on the definitions and anal yses for the tertiary /exploratory  endpoints specified in 
Section 3 will be described in the SAP.
9.3.5. Safety Analyses
All safet y anal yses will be performed on the safet y population. Safety data including AEs, 
SAEs, AEs leading to discontinuation, vital signs, and clinical laboratory  data will be 
summarized descriptively through appropriate data tabulation, descr iptive statistics, 
categorical summaries, and graphical presentations in accordance with Pfizer Data Standards.
9.3.6. Other Analyses 
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during or after the trial and retained for fut ure analy ses; the results of such anal yses are not 
planned to be included in the CSR. 
PRO data (ie, SF -36, WPAI, EQ -
5D-5L) will be collected during the trial and are not planned 
to be included in the CSR. 
The following anal yses will be described in a sep arate report and will not be included in the 
CSR:
New viral lineages and/or treatment -emergent mutations with demonstrated reduced 
susceptibility  to study  intervention in vitro will be anal yzed to determine the 
emergence of virus with reduced susceptibilit y in participants with mild -to-moderate 
COVID -19.
9.4.Interim Analyses
No formal interim anal ysis is planned for this study . However, the sponsor may  conduct 
unblinded reviews of the data during the course of the study  if requested b y regulatory  
authorities including in the support of regulatory  submissions. Should an unblinded review 
be requested, details of the unblinding plan will be described in the SAP and a separate data 
unblinding document.
9.5.Sample Size Determination
The study
 will enroll approximately  411 participants.
The sample size calculation is based on the primary efficacy  endpoint as the change in viral 
RNA level from baseline to Day  5 as measured in NP swabs in the mI TT analy sis set. 
Assuming a SD of 1.8 (based on EPI C
-HR, [STUDY_ID_REMOVED]), a sample s ize of approximately  
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 78315 evaluable participants (210 participants in nirmatrelvir/ritonavir group and 105 
participants in placebo/ritonavir group) is expected to provide 90% power to detect a 
difference of 0.7 log 10copies/mL  in viral RNA between groups using a 2 -sided 0.05 alpha 
level test. Assuming approximately  10% of participants will have a negative viral RNA result 
at baseline, and assuming a non -evaluable rate of 15%, approximately  411 participants will 
be randomized in the study  to achieve approxima tely 315 participants evaluable for the 
primary  efficacy  endpoint. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 7910. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents (eg, 
advertisements) must be reviewed and approved by the sponsor , submitted to an I RB/EC by  
the investigator , and reviewed and approved by  the I RB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsibl e for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an app licable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately . 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 80of an y serious breaches of this protocol or of the ICH GCP  guidelines that the investiga tor 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent/Assent Process 
10.1.3.1. Informed Cons ent Process
The investigator or the investigator ’s representative will explain the nature of the study , 
including the risks and benefits, to the participant or their legall y authorized representative
and answer all questions regarding the stud y. The partic ipant or their legally  authorized 
representative should be given suf ficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants ortheir legally  
authorized representative (if allowed b y local regulations) will be required to sign a statement 
of informed consent that meets the requirements of 21 CFR 50, local regulations, I CH 
guidelines, privacy  and data protection requirements, where applicable, and the I RB/EC or 
study  center .
The investigator must ensure that each participant or their legall y authorized representative is 
fully  informed about the nature and objectives of the study , the sharing of data related to the 
study , and possibl e risks associated with participation, including the risks associated with the 
processing of the participant
’s personal data. 
The participant or their legall y authorized representative must be informed that their personal 
study -related data will be used b y the sponsor in accordance with local data protection law . 
The level of disclosure must also be explained to the participant or their legally  authorized 
representative .
The participant or their legall y authorized representative must be informed that their medical 
records may  be examined by  Clinical Qualit y Assurance auditors or other authorized 
personnel appointed b y the sponsor , by appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities.
The investigator further must ensure that each stu dy participant or their legally  authorized 
representative is fully  informed about their right to access and correct their personal data and 
to withdraw consent for the processing of their personal data.
The medical record must include a statement that writ ten informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 81Participants or their legally  authorized representative must be reconsented to the most current 
version of the IRB/EC -approved ICD(s) during their participation in the study  as required per 
local regulations.
A copy of the ICD(s) must be provided to the participant or their legall y authorized 
representative (if allowed by  local regulations) .
10.1.3.2. Informed Assent Process
The investigator or their representative will explain the nature of the study  to the participant 
and their parent(s)/legal guardian and answer all questions regarding the study . The 
participant and their parent(s)/legal guardian should be given sufficient time and opportunity  
to ask questions and to decide whether or not to participate in the trial. 
When consent is obtained from a participant’s parent(s)/legal guardian, the participant ’s 
assent (affirmative agreement) must be subsequently  obtained when the participant has the 
capacity  to provide assent, as determined by  the IRB/EC. If the investigator determines that a 
participant’s decisional capacit y is so limited they cannot reasonab ly be consulted, then, as 
permitted by  the IRB/EC and consistent with local regulatory  and legal requirements, the 
participant’s assent may  be waived with source documentation of the reason assent was not 
obtained. If the stud y participant does not provide their own assent, the source documents 
must record wh y the participant did not provide assent (for example, the child is not of 
assenting age per local regulations or policies), how the investigator determined that the 
person signing the consent was the p articipant’s parent(s)/legal guardian, the consent signer’s 
relationship to the study  participant, and that the participant’s assent was obtained or waived. 
If assent is obtained verbally , it must be documented in the source documents. 
If study  participan ts are minors who reach the age of majorit y or if a child reaches the age of 
assent (per local IRB/EC requirements) during the study , as recognized under local law, the 
child or adolescent must then provide the appropriate assent or consent to document the ir 
willingness to continue in the study . For an adolescent who reaches the age of consent, 
parental consent would no longer be valid. If the enrollment of emancipated minors is 
permitted by  the IRB/EC and local law, the participant must provide documentati on of legal 
status to give consent without the permission of a legally  authorized representative. 
Participants and their parent(s)/legal guardian must be informed that their participation is 
voluntary . The participant’s parent(s)/legal guardian will be re quired to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, I CH 
guidelines, HI PAA requirements, where applicable, and the IRB/EC or study  center. 
The investigator must ensure that each study  participant’s pa rent(s)/legal guardian and the 
study  participant as applicable are full y informed about the nature and objectives of the 
study , the sharing of data related to the study , and possible risks associated with 
participation, including the risks associated with the processing of the participant’s personal 
data.  
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 82The participant’s parent(s)/legal guardian must be informed that the participant’s personal 
study -related data will be used by  the sponsor in accordance with local data protection law. 
The level of disclosure must also be explained to the participant’s par ent(s)/legal guardian. 
The participant’s parent(s)/legal guardian must be informed that the participant’s medical 
records may  be examined by  Clinical Qualit y Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities. 
The investigator further must ensure that each study  participant’s parent(s)/legal guardian is 
fully  informed about their right to access and correct their child’s personal data and to 
withdraw conse nt for the processing of their child’s personal data, keeping in mind the 
privacy  rights that may  restrict access of older adolescents’ medical records by  their 
parent(s)/legal guardian in certain regions. 
The source documentation must include a statement that written informed consent, and as 
applicable, assent was obtained before the participant was enrolled in the study  and the date 
the written consent/assent was obtained. The authorized person obtaining the informed 
consent must also sign the I CD. 
Parent(s)/legal guardian and the participant must be reconsented to the most current version 
of the I CD(s)/assent during their participation in the study  as required per local regulations. 
A cop y of the ICD(s) and assent, if written, must be provided to the p arent(s)/legal guardian 
and the participant.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password protected to ensure that onl y authorized study  staff have access. The stud y 
site will implement appropriate technical and organizational measures to ensure that th e 
personal data can be recovered in the event of disaster . In the event of a potential personal 
data breach, the stud
y site will be responsible for determining whether a personal data breach 
has in fact occurred and, if so, providing breach notifications a s required by law .
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant -specific code. The study site will 
maintain a confidential list of participants who participated in the study , linking each 
participant ’s numerical code to their actual identity  and medical record ID. In case of data 
transfer , the sponsor will protect the confidentiality  of participants’ personal data consistent 
with the clinical study  agreement and applicable privacy  laws.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 83Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to protect such data 
against accidental or u nlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or sy stems.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee 
This study  will use an E- DMC . The E -DMC is independent of the stud y team and includes 
only external members. The E- DMC charter describes the role of the E- DMC in more detail.
The E- DMC will be responsible for ongoing monitoring of the safet y of participants in the 
study  according to the charter. In addition, the E- DMC may  monitor the baseline SARS -
CoV -2 RNA levels to ensure the population is consistent with the study  design assumptions. 
The recommendations made b y the E -DMC will be forwarded to the appropriate a uthorized 
Pfizer personnel for review and final decision. Pfizer will communicate such decisions, 
which may  include summaries of aggregate safety  data, to regulatory  authorities and 
investigators, as appropriate. 
10.1.6. Dissemination of Clinical Study Data
Pfize r fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www .clinicaltrials.gov (ClinicalT rials.gov), the EudraCT/CTI S, and/or 
www .pfizer .com, and other public registries and websites in accordance wit h applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www .clinicaltrials.gov for Pfizer -sponsored interventional 
studies (conducted in p atients) that evaluate the safety  and/or ef ficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT/CTI S
Pfizer posts clinical trial results on EudraCT/CTI S for Pfizer -sponsored interventional studies 
in accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts CSR sy nopses and plain- language study  results summaries on www .pfizer .com 
for Pfizer -sponsored interventional studies at the same time the corresponding study  results 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 84are posted to www.clinicaltrials.gov. CSR sy nopses will have personally  identifiable 
information anon ymized.
Documents within marketing applications
Pfizer complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
Pfizer provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona -fide scientific research” that contributes to the scientific underst anding of 
the disease, target, or compound class. Pfizer will make data from these trials available 
18months after study  completion. Participant -level data will be anon ymized in accordance 
with applicable privacy  laws and regulations. CSRs will have personall y identifiable 
information anon ymized.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy
ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF .
Guidance on completion of CRFs will be provided in t he CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic form and are password protected to prevent access by  unauthorized third parties.
QTL s are predefined parameter s that are monitored during the study . Important deviations 
from the QTLs and an y remedial actions taken will be summarized in the CSR.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and prov ide direct access to source records and documents. 
This verification may  also occur after study  completion. I t is important that the 
investigator(s) and their relevant personnel are available during the monitoring visits and 
possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk
-based initiatives in operations and quality  such as risk management and 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 85mitigation strateg ies and anal ytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by  the sponsor or designee. 
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor . No records may  be 
transferred to another location or part y without written notification to the sponsor . The 
investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify
 the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site an d investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the partic ipant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancie s must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the S ource 
Document Locator , which is maintained by  the sponsor .
Description of the use of the computerized sy stem is documented in the Data Management 
Plan, which is maintained by  the sponsor .
The investigator must maintain accurate documentation (source data)that supports the 
information entered in the CRF .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 86The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by authorized site personnel are accurate, complete, and verifiable from source documents; 
that the safet y and righ ts of participants are being protected; and that the study  is being 
conducted in accordance with the currentl y approved protocol and an y other study  
agreements, I CH GCP  guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closur e
The study  start date is the date of the first participant’s first visit.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor , including (but not limited t o) 
regulatory  authorit y decision, change in opinion of the I RB/EC, or change in benefit -risk 
assessment. Study  sites will be closed upon study completion. A study  site is considered 
closed when all required documents and study  supplies have been collected and a stud y-site 
closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;
Inadequate recruitment of participants by  the investigator; 
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
For multicenter trials, the primary  publication will be a joint publication developed b y the 
investigator and Pfizer reporting the primary  endpoint(s) of the study  covering all study  sites. 
The investigator agrees to refer to the primary publication in any  subsequent publications. 
Pfizer will not provide any financial compensation for the investigator’s participation in the 
preparation of the primary congress abstract, poster, presentation, or primary manuscript for 
the study .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 87Investigators are free to publish individual center results that they  deem to be clinically  
meaningful after publication of the overall results of the study  or 12 months after primary  
completion date or stud y completion at all sites, whichever occurs first, subject t o the other 
requirements described in this section.
The investigator will provide Pfizer an opportunity  to review any  proposed publication or 
any other t ype of disclosure of the stud y results (collectively , “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to Pfizer 30 days before 
submission. If an y patent action is required to protect intellectual propert y rights, the 
investigator agrees to delay  the disclosure for a period not to exceed an additional 60 day s 
upon request from Pfizer. This allows Pfizer to protect proprietary  information and to provide 
comments, and the investigator will, on request, remove an y previousl y undisclosed 
confidential information before disclosure, except for an y stud y
-intervention or 
Pfizer -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results. For joint publications, should there be disagreement 
regarding interpretation and/or presentation of specific anal ysis results, resolut ion of, and 
responsibility  for, such disagreements will be the collective responsibility  of all authors of 
the publication.
For all publications relating to the stud y, the investigator and Pfizer will comply with 
recognized ethical standards concerning pub lications and authorship, including those 
established by  the International Committee of Medical Journal Editors. The investigator will 
disclose an y relationship with Pfizer and any relevant potential conflicts of interest, including 
any financial or person al relationship with Pfizer, in any  publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.
10.1.11. Sponsor’s Medically Qualified Individual 
The contact in formation for the sponsor’ s MQI for the study  is documented in the study  
contact list located in the supporting stud y documentation/study  portal or other electronic 
system .
To facilitate access to their investigator and the sponsor’ s MQI for study -related medical 
questions or problems from non- study  healthcare professionals, participants are provided 
with an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol 
and study  intervention identifiers, (b) participant’ s study  identific ation number , (c) site 
emergency phone number active 24 hours/day , 7 day s per week, and (d) Pfizer Call Center 
number .
The ECC is intended to augment, not replace, the established communication pathway s 
between the participant and their investigator and si te staf f, and between the investigator and 
sponsor study  team. The ECC is only  to be used by  healthcare professionals not involved in 
the research study , as a means of reaching the investigator or site staf f related to the care of a 
participant. The Pfizer Call Center number is to be used when the investigator and site staff 
are unavailable. The Pfizer Call Center number is not for use by  the participant directl y; if a 
participant calls that number directly , they  will be directed back to the investigator site.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 8810.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  the clinical laboratory , or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at a ny time during the 
study  to assess an y perceived safet y issues.
Table 2. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Other Reflex Testing
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)Urea 
Serum creatinine and 
eGFR (calculated)a
Glucose 
Sodium
Potassium
Chloride
Total CO2 (bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseViral Serology
SARS -CoV-2
At screening:
FSHb
Pregnancy test 
(β-hCG)c
HIV testingdFor suspected DILI:
AST/ALT 
Total bilirubin, direct and 
indirect bilirubin 
Total bile acids, GGT 
Total protein, albumin CK 
PT, INR 
Acetaminophen/paracetamol or 
protein adduct levels 
Hepatitis serology
a.eGFR will be calculated using the method developed by the 2021 CKD -EPI (Scr only) for participants 
18 years or older or eCrCl using the Cockcroft -Gault formula for participants 12 years to <18 years.
b.FSH testing is performed locally when needed to confirm postmenopausal status at screening.
c.Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/EC. Serum or urine -hCG for female participants of childbearing potential.
d.Local HIV testing at screening w ill be performed for participants in Germany as required by the German 
HA.
The investigator must review the laboratory  report, document this review , and record an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF .   
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 8910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluati ng, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  inter vention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medica l and scientific judgment of the investigator. An y abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical interv ention.
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting con dition, including an 
increase in either frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration, even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the cl inical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intention al overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 90Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur ( social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospit alization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary , the 
AE should be considered serious.
Hospitalization for el ective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 91An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious agent, pathogenic 
or nonpathogenic  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a Pfizer product. The terms “ suspected 
transmission” and “transmission ” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by  the investigator in deciding 
whether SAE reporting is app ropriate in other situations, such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be conside red serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug 
depende ncy or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AEs and/or SAEs During the Active 
Collection Period 
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs using the PSSA to Pfizer Safety throughout the active collection period. 
These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious AEs; and 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 92(3) exposure to the study  intervention under study  during pregnancy  or breastfeeding, and 
occupational exposure. 
It should be noted that the PSSA for reporting of SAE information is not the same as the 
AE page of the CRF. When the same data are collected, the forms must be completed in a 
consistent manner. AEs should be recorded using concise medical terminology  and the 
same AE term should be used on both the CRF and the PSSA for reporting of SAE 
information.
Safety Event Recorded on the CRF Reported u sing the PSSA 
to Pfizer Safety Within 24 
Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding All AEs or SAEs associated 
with EDP or EDB
Note: I nstances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRFAll instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE)**
Environmental or 
occupational exposure to 
the product under stud y to 
a nonparticipant (not 
involving EDP or EDB)None. Exposure to a study 
nonparticipant is not 
collected on the CRFThe exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*EDP (with or witho ut an associated AE or SAE): any pregnancy information is reported to Pfizer 
Safety using the PSSA; if the EDP is associated w ith an SAE, then the SAE is reported to Pfizer Safety 
using the PSSA. 
** EDB is reported to Pfizer Safety using the PSSA, which would also include details of any SAE that 
might be associated w ith the EDB. 
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to Pfizer Safety using the PSSA. 
When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 93It is notaccept able for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the PSSA/AE or SAE 
CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety . In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based o n signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories, which are based on the 
DAIDS Table for Grading the Severity  of Adult and Pediatric Adverse Events[ 30], version 
2.1 (July  2017): 
GRADE Clinical Description of Severity
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 POTENTIALLY LIFE -THREATENING event 
5 DEATH RELATED TO adverse event
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, wil l be considered and investigated.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 94Assessment of Causality
The investigator will also consult the IB and/or product information, for marketed 
products, in their assessment.
For each AE or SAE, the investigator must document in the medical notes that they  
have reviewed the AE or SA E and have provided an assessment of causality.
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always ma ke an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
The investigator may  change their opinion of causality  in light of follow -up 
information and send an SAE follow-up report with the updated causali ty 
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention” for reporting 
purposes, as defined b y the sponsor. In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and r eport such an 
assessment in the dedicated section of the PSSA and in accordance with the SAE 
reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evalua tions, as medically  indicated or as requested by  the 
sponsor, to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation wi th other healthcare providers.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings, including histopathology . 
New or updated in formation will be recorded in the originally  submitted 
documents.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 9510.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic DCT
The primary  mechanism for reporting an SAE to Pfizer Safety  will be the 
electronic DCT (PSSA).
If the electronic s ystem is unavailable, then the site will use the paper form ( see 
next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic DCT (PSSA) or paper form (as 
applicable) as soon as the data become available.
After the stud y is completed at a given site, the electronic DCT will be taken 
off-line to prevent the entry  of new data or changes to existing data.
Ifa site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic DCT has been taken off -line, 
then the site can report this information on a paper SAE form (see next section) or 
to Pfizer Safety  by telephone.
SAE Reporting to Pfizer Safety via the CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working, an alternative method should 
be used, eg, secured (Transport L ayer Security ) or password- protected email. I f 
none of these methods can be used, notification b y telephone is acceptable with a 
copy  of the CT SAE Report Form sent by  overnight mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 9610.4. Appendix 4: Contraceptive and Barrier Guidance 
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥100-fold between the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in nonclinical studies. 
10.4.1. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1) and specify  
the reproductive requirements for including female participants. Refer to Section 10.4.3 for a 
complete list 
of contraceptive methods permitted in the study . 
A female participant is eligible to participate if at least 1 of the following conditions applies:
Is not a WOCBP (see definition in Section 10.4.2).
OR
Is a WOCBP who is pregnant (at least 14 weeks gestation).
OR
Is a WOCBP who is not pregnant at screening and agrees to use a highly  effective 
contraceptive method (failure rate of <1% p er year) during the intervention period 
and for at least 28 day s after the last dose of stud y intervention, which corresponds to 
the time needed to eliminate an y reproductive safety risk of the stud y intervention(s). 
If a highl y effective, user-dependent method is chosen, she agrees to concurrentl y use 
an effective barrier method of contraception. The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.2. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenarchal.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 972.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to a medical cause other than the above (eg, 
mullerian agenesis, androgen insensitivity ), investigator discretion should be applied to 
determining stud y entr y.
Note: Documentation for any  of the above categories can come from the site pers onnel ’s 
review of the participant ’s medical records, medical examination, or medical history  
interview . The method of documentation should be recorded in the participant ’s medical 
record for the study.
3.Postmenopausal female:
A postmenopausal state is defin ed as no menses for 12 months without an alternative 
medical cause. In addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 50 years of age and not using hormonal 
contraception or HRT. 
A fema le on HRT and whose menopausal status is in doubt will be required to 
use one of the highl y effective nonestrogen hormonal contraception methods 
if she wishes to continue her HRT during the study . Otherwise, she must 
discontinue HRT to allow confirmation o f postmenopausal status before study  
enrollment.
10.4.3. Contraception Methods 
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The fo llowing contraceptive methods are appropriate for this study :
Highl y Effective Methods That Have Low User Dependency  
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 985.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an add itional highly  effective method of contraception should be 
used. The spermatogenesis cy cle is approximately  90 day s.
Highl y Effective Methods That Are User Dependent 
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with in hibition of ovulation:
Oral + barrier*
Intravaginal + barrier*
Transdermal + barrier*
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral + barrier*
Injectable + barrier*
Sexual Abstinence
8.Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.
* Acceptable barrier methods to be used concomitantly  with options 6 or 7 for the study  
include an y of the following:
Male or female condom, with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge 
with spermicide (double -barrier methods).
Because ritonavir may  reduce the effect of estradiol- containing contraceptives when agents 
are co -
administered, a barrier method or other nonhormonal method of contraception should 
be considered if the participant is using estradiol
-containing contraceptives during the 5 day s 
of nirmatrelvir/ritonavir treatment and until 1 menstrual cy cle after stopping 
nirmatrelvir/r itonavir.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 9910.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRBs/ECs allow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  be narrow (eg, 1 or more candidate genes) or 
broad (eg, the entire genome), as appropriate to the scientific question under 
investigation.
The samples may  be analy zedas part of a multistudy  assessment of genetic factors 
involved in the response to nirmatrelvir/ritonavir or study interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic anal yses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confide ntiality . 
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or for another period as per local 
requirements. 
Participants may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y time by  making a request to the investigator; in this case, 
any remaining material will be destroy ed. Data already  generated from the samples 
will be retained to protect the integrit y of existing anal yses. 
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant’s personally  identify ing information (eg, name, address) will be 
held securely at the study site. 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 10010.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments and 
Study Interve ntion Rechallenge Guidelines
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “ tolerators, ” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible ” to progressive and serious liver injury , commonly  referred to a s DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptors ” or are “ susceptible. ”
LFTs are not required as a routine safety  monitoring procedure in this study . However , should 
an investigator deem it necessary  to assess LFT s because a participant presents with clinical 
signs/sy mptoms, such LFT  results should be managed and followed as described below .
In the majority  of DILI cases, elevations in AST
 and/or ALT precede T bili elevations (>2 × 
ULN) b y several days or weeks. The increase in T bili ty pically  occurs while AST/AL T is/are 
still elevated above 3 × ULN (ie, AST/AL T and T bili values will be elevated within the same 
laboratory  sample). In rare instances, by  the time T bili elevations are detected, AST/AL T 
values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, 
abnormal elevations in either AST OR ALT in addition to T bili that meet the criteria outlined 
below are considered pote ntial DILI (assessed per Hy ’s law criteria) cases and should alway s 
be considered important medical events, even before all other possible causes of liver injury  
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depend s on the 
participant ’s individual baseline values and underly ing conditions. Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy
’s law) cases to definitively  determine the etiology  of the a bnormal laboratory  values:
Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bili value 
≥2×ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values 
≥2times the baseline values AND ≥3 ×ULN; or ≥8 ×ULN (whichever is 
smaller).
Preexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of ≥1 × ULN orif the value reaches ≥3×ULN 
(whichever is smaller).
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 101Rises in AST/AL T and T bili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy ’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include labo ratory  tests, detailed history , and ph ysical assessment.
In addition to repeating measurements of AST and ALT and T bili for suspected Hy ’s law 
cases, additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT , PT/I NR, tota l bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medications), recreationa l drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history , history  of contact 
with a jaundiced person, sur gery, blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
Tbili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT  abnormalities has y et been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 10210.7. Appendix 7: Age -Specific Kidney Function Calculation Recommendations
10.7.1. Adults (18 Years and Above)—2021 CKD- EPI Equations
eGFR (mL/min/1.73 m2)
2021 CKD -
EPI            
Scr OnlyScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 N/A eGFR = 143 × (Scr/0.7)-0.241  ×  (0.9938)Age
Female if > 0.7 N/A eGFR = 143 × (Scr/0.7)-1.200  ×  (0.9938)Age
Male if ≤ 0.9 N/A eGFR = 142 × (Scr/0.9)-0.302  ×  (0.9938)Age
Male if> 0.9 N/A eGFR = 142 × (Scr/0.9)-1.200  ×  (0.9938)Age
Inker LA et al. N Engl J Med. 2021;385:1737 -49 [32]. 
10.7.1.1. Adolescents (12 Years to <18 Years) —Cockcroft -Gault Formula
CrCl (mL /min) 
Males:  C r/Cl = [(140 
–age) × bod y weight (in kg)] / [Scr (in mg/dL) × 72]
Females: Cr/Cl = 0.85 × [(140 –age) × bod y weight (in kg)] / [Scr (in mg/dL) × 72]
10.7.2. Adverse Event Grading for Kidney Safety Laboratory Abnormalities
AE grading for decline in kidney  functi on (ie, eGFR or eCrCl) will be according to KDIGO 
criteria.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 10310.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That May 
Result in DDI 
Nirmatrelvir and ritonavir are both primarily  metabolized by  CYP3A4. Therefore, 
concomitant use of an y medi cations or substances that are strong inducers of CYP3A4 and 
that are contraindicated in combination with nirmatrelvir/ritonavir are prohibited without the 
appropriate washout prior to the first dose of study  intervention.
Nonexhaustive lists of prohibited and precautionary medications are provided below in Table 
3, and Table 4 respectively . If a medication is not listed as contraindicated, it should not 
automatically  be assumed it is safe to coadminister. Appropriatel y qualified site staff will 
review all concomitant medications to determine if they  are prohibited. 
The Pfizer study  team 
is to be notified of any prohibited medications taken during the study. After consulting with 
the sponsor, the investigator will make a judgment on the ongoing participation of any  
participant with prohibited medication use during the study .
This list of drugs prohibited for potential DDI concerns with the stud y intervention may be 
revised during the course of the study  with written notification from sponsor, to include or 
exclude specific drugs or drug categories for various reasons ( eg, emerging DDI results for 
the IMP, availability  of new information in literature on the DDI potential of other drugs).  
This is not an all -inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI .
Table 3 lists the drugs prohibited for use with nirmatrelvir/ritonavir, and Table 4lists 
clinically  signific ant (precautionary ) drugs. The drugs listed in Table 3 and Table 4 are a 
guide and not considered a comprehensive list of all possible drugs that may  interact with 
nirmatrelvir/ritonavir. The healthcare provider should consult appropriate references, such as 
the prescribing information for the interacting drug for comprehensive in formation on dosing 
or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.
Table 3. Drugs That are Contraindicated With Nirmatrelvir/Ritonavir 
Drug Class Drugs Within 
ClassEffect on Concentration Clinical Comments
Alpha 1 -adrenoreceptor 
antagonistalfuzosin ↑ alfuzosin Co-administration 
contraindicated due to 
potential hypotension. 
Antianginal ranolazine ↑ ranolazine Co-administration 
contraindicated due to 
potential for serious and/or 
life-threatening reactions.
Antiarrhythmics amiodarone, 
dronedarone, 
flecainide, 
propafenone, 
quinidine↑ antiarrhythmic Co-administration 
contraindicated due to 
potential for cardiac 
arrhythmias.
Anticancer drugs apalutamide ↓ nirmatrelvir/ritonavir Co-administration 
contraindicated due to 
potential loss of virologic 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 104Table 3. Drugs That are Contraindicated With Nirmatrelvir/Ritonavir 
Drug Class Drugs Within 
ClassEffect on Concentration Clinical Comments
response and possible 
resistance.
Anticonvulsants carbamazepine,
phenobarbital,
primidone,
phenytoin↓ nirmatrelvir/ritonavir Co-administration 
contraindicated due to 
potential loss of virologic 
response and possible 
resistance.
Anti-gout colchicine ↑ colchicine Co-administration 
contraindicated due to 
potential for serious and/or 
life-threatening reactions in 
patients with renal and/or 
hepatic impairment.
Antimycobacterial rifampin,
rifapentine↓ nirmatrelvir/ritonavir Co-administration 
contraindicated due to 
potential loss of virologic 
response and possible 
resistance. Alternate 
antimycobacterial drugs 
such as rifabutin should be 
considered.
Antipsychotics lurasidone, 
pimozide↑ lurasidone
↑ pimozideCo-administration 
contraindicated due to 
serious and/or 
life-threatening reactions 
such as cardiac 
arrhythmias.
Benign prostatic 
hyperplasia agentssilodosin ↑ silodosin Co-administration 
contraindicated due to 
potential for postural 
hypotension.
Cardiovascular agents eplerenone
ivabradine↑ eplerenone
↑ ivabradineCo-administration with 
eplerenone is 
contraindicated due to 
potential for hyperkalemia.
Co-administration with 
ivabradine is 
contraindicated due to 
potential for
bradycardia or conduction
disturbances.
Cystic fibrosis 
transmembrane 
conductance regulator 
potentiatorslumacaftor/ivacaftor ↓ nirmatrelvir/ritonavir Co-administration 
contraindicated due to 
potential loss of virologic 
response and possibl e 
resistance. 
Ergot derivatives dihydroergotamine,
ergotamine,
methylergonovine↑ dihydroergotamine
↑ ergotamine
↑ methylergonovineCo-administration 
contraindicated due to 
potential for acute ergot 
toxicity characterized by 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 105Table 3. Drugs That are Contraindicated With Nirmatrelvir/Ritonavir 
Drug Class Drugs Within 
ClassEffect on Concentration Clinical Comments
vasospasm and ischemia of 
theextremities and other 
tissues including the central 
nervous system.
Herbal products St. John’s Wort 
(hypericum 
perforatum )↓ nirmatrelvir/ritonavir Co-administration 
contraindicated due to 
potential loss of virologic 
response and possible 
resistance.
HMG- CoA reductase 
inhibitorslovastatin,
simvastatin↑ lovastatin
↑ simvastatinCo-administration 
contraindicated due to 
potential for myopathy 
including rhabdomyolysis.
Discontinue use of 
lovastatin and 
simvastatin at least 12 
hours prior to initiatio n of 
nirmatrelvir/ritonavir, 
during the 5 days of 
nirmatrelvir/ritonavir 
treatment, and for 5 days 
after completing 
nirmatrelvir/ritonavir.
Immunosuppressants voclosporin ↑ voclosporin Co-administration 
contraindicated
due to potential for acute 
and/or
chronic nephrotoxicity.
Microsomal triglyceride 
transfer protein inhibitorlomitapide ↑ lomitapide Co-administration 
contraindicated due to 
potential for hepatotoxicity 
and gastrointestinal adverse 
reactions.
Migraine medications eletriptan
ubrogepant↑ eletriptan
↑ ubrogepantCo-administration of 
eletriptan within at least 72 
hours of 
nirmatrelvir/ritonavir is
contraindicated due to 
potential for serious 
adverse reactions including 
cardiovascular and 
cerebrovascular events.
Co-administration of 
ubrogepant with
nirmatrelvir/ritonavir is 
contraindicated due to
potential for serious 
adverse
reactions.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 106Table 3. Drugs That are Contraindicated With Nirmatrelvir/Ritonavir 
Drug Class Drugs Within 
ClassEffect on Concentration Clinical Comments
Mineralocorticoid 
receptor antagonistsfinerenone ↑ finerenone Co-administration 
contraindicated due to 
potential for serious 
adverse reactions including 
hyperkalemia, hypotension, 
and hyponatremia.
Opioid antagonists naloxegol ↑ naloxegol Co-administration 
contraindicated due to the 
potential for opioid 
withdrawal symptoms 
Pulmonary hypertension 
agent (PDE5 inhibitor)sildenafil 
(Revatio®) ↑ sildenafil Co-administration of 
sildenafil with 
nirmatrelvir/ritonavir is 
contraindicated due to the 
potential for sildenafil 
associated adverse events, 
including visual 
abnormalities, hypotension, 
prolonged erection, and 
syncope. 
Sedative/hypnotics triazolam, 
oral midazolam↑ triazolam
↑ midazolam Co-administration 
contraindicated due to 
potential for extreme 
sedation and respiratory 
depression. 
Serotonin receptor 1A 
agonist/serotonin 
receptor 2A antagonist flibanserin ↑ flibanserin Co-administration 
contraindicated due to 
potential for hypotension, 
syncope, and CNS 
depression.
Vasopressin receptor 
antagoniststolvaptan ↑ tolvaptan Co-administration 
contraindicated due to 
potential for dehydration, 
hypovolemia and 
hyperkalemia.
Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Alpha 1 -
adrenoreceptor 
antagonisttamsulosin ↑ tamsulosin Avoid concomitant use with 
nirmatrelvir/ritonavir.
Antiarrhythmics lidocaine (systemic),
disopyramide↑ antiarrhythmic Caution is warranted and 
therapeutic concentration 
monitoring is recommended for 
antiarrhythmics if available.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 107Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Anticancer drugs abemaciclib, 
ceritinib,
dasatinib, 
encorafenib,
ibrutinib, 
ivosidenib, 
neratinib, 
nilotinib, 
venetoclax,
vinblastine, 
vincristine↑ anticancer drug Avoid co -administration of 
encorafenib or ivosidenib due 
to potential risk of serious 
adverse events such as QT 
interval prolongation. Avoid 
use of neratinib, venetoclax or 
ibrutinib.
Co-administration of 
vincristine and vinblastine may 
lead to significant hematologic 
or gastrointestinal side effects.
For further information, refer 
to individual product label for 
anticance r drug.
Anticoagulants warfarin
rivaroxaban
dabigatran
apixaban↑↓ warfarin
↑ rivaroxaban
↑ dabigatran
↑ apixabanClosely monitor INR if 
co-administration with 
warfarin is necessary.
Increased bleeding risk with 
rivaroxaban. Avoid 
concomitant use.
Increased bleeding risk with 
dabigatran. Depending on 
dabigatran indication and renal 
function, reduce dose of 
dabigatran or avoid 
concomitant use. Refer to the 
dabigatran product label for 
further information.
Com bined P-gp and strong 
CYP3A4 inhibitors increase 
blood levels of apixaban and 
increase the risk of bleeding. 
Dosing recommendations for 
co-administration of apixaban 
with nirmatrelvir/ritonavir 
depend on the apixaban dose. 
Refer to the apixaban product 
label f or more information.
Anticonvulsants clonazepam ↑ anticonvulsant A dose decrease may be 
needed for clonazepam when 
co-administered with 
nirmatrelvir/ritonavir and 
clinical monitoring is 
recommended.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 108Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Antidepressants bupropion
trazodone↓ bupropion and 
active metabolite 
hydroxy -bupropion 
↑ trazodoneMonitor for an adequate 
clinical response to bupropion. 
Adverse reactions of nausea, 
dizziness, hypotension, and 
syncope have been observed 
following co -administration of 
trazodone and ri tonavir. A 
lower dose of trazodone should 
be considered. Refer to 
trazadone product label for 
further information. 
Antifungals voriconazole,
ketoconazole, 
isavuconazonium sulfate,
itraconazole↓ voriconazole 
↑ ketoconazole
↑ isavuconazonium 
sulfate
↑ itraconazole
↑ 
nirmatrelvir/ritonavir Avoid concomitant use of 
voriconazole.
Refer to ketoconazole, 
isavuconazonium sulfate, and 
itraconazole product labels for 
further information.
A nirmatrelvir/ritonavir dose 
reduction is not needed.
Anti-HIV protease 
inhibitorsatazanavir,
darunavir,
tipranavir ↑ protease inhibitor For further information, refer 
to the respective protease 
inhibitors’ prescribing 
information.
Patients on ritonavir -or 
cobicistat -containing HIV 
regimens should continue their 
treatment as indicated. Monitor 
for increased 
nirmatrelvir/ritonavir or 
protease inhibitor adverse 
events.
Anti-HIV efavirenz,
maraviroc,
nevirapine,
zidovudine,
bictegravir/
emtricitabine/ 
tenofovir↑ efavirenz
↑ maraviroc
↑ nevirapine
↓ zidovudine
↑bictegravir
↔ em tricitabine
↑ tenofovirFor further information, refer 
to the respective anti -HIV 
drugs prescribing information.
Anti-infective clarithromycin,
erythromycin↑ clarithromycin
↑ erythromycinRefer to the respective 
prescribing information for 
anti-infective dose adjustment.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 109Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Antimycobacterial bedaquiline
rifabutin↑ bedaquiline
↑ rifabutinRefer to the bedaquiline 
product label for further 
information.
Refer to rifabutin product label 
for further information on 
rifabutin dose reduction.
Antipsychotics quetiapine
clozapine↑ quetiapine
↑ clozapineIf co-administration is 
necessary, reduce quetiapine 
dose and monitor for 
quetiapine -associated adverse 
reactions. Refer to the 
quetiapine prescribing 
information for
recommendations.
If co-administration is 
necessary, consider reducing 
the clozapine dose and monitor 
for adverse reactions.
Calcium channel 
blockersamlodipine, 
diltiazem,
felodipine,
nicardipine,
nifedipine,
verapamil↑ calcium channel 
blockerCaution is warranted and 
clinical monitoring of patients 
is recommended. A dose 
decrease may be needed for 
these drugs when 
co-administered with 
nirmatrelvir/ritonavir.
If co-administered, refer to 
individual product label for 
calcium channel blocker for 
further information.
Cardiac glycosides digoxin ↑ digoxin Caution should be exercised 
when co -administering 
nirmatrelvir/ritonavir with 
digoxin, with appropriate 
monitoring of serum digoxin 
levels. 
Refer to the digoxin product 
label for further information.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 110Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Cardiovascular 
agentsaliskiren,
ticagrelor,
vorapaxar
clopidogrel
cilostazol↑ aliskiren
↑ ticagrelor
↑ vorapaxar
↓ clopidogrel active 
metabolite
↑ cilostazolAvoid concomitant use with  
nirmatrelvir/ritonavir.
Dosage adjustment of
cilostazol is recommended. 
Refer to the cilostazol product 
label for more information.
Corticosteroids 
primarily 
metabolized by 
CYP3Abetamethasone,
budesonide,
ciclesonide,
dexamethasone,
fluticasone,
methylprednisolone,
mometasone,
triamcinolone↑ corticosteroid Co-administration with 
corticosteroids ( all routes of 
administration) of which 
exposures are significantly 
increased by strong CYP3A 
inhibitors can increase the risk 
for Cushing’s syndrome and 
adrenal suppression.  How ever, 
the risk of Cush ing’s syndrome 
and adrenal suppression 
associated with short -term use 
of a strong CYP3A inhibitor is 
low.
Alternative corticosteroids 
including beclomethasone, 
prednisone, and prednisolone 
should be considered.
Cystic fibrosis 
transmembrane 
conductance 
regulator 
potentiatorsivacaftor
elexacaftor/tezacaftor/
ivacaftor
tezacaftor/ivacaftor↑ ivacaftor
↑ 
elexacaftor/tezacafto
r/ivacaftor
↑ tezacaftor/ivacaftorReduce dosage when co -
administered with 
nirmatrelvir/ritonavir.
Refer to individual product 
labels for further information.
Dipeptidyl 
peptidase 4 
inhibitorssaxagliptin ↑saxagliptin Dosage adjustment of 
saxagliptin is recommended. 
Refer to the saxagliptin product 
label for more information.
Endothelin 
receptor
antagonistsbosentan ↑ bosentan
↓ 
nirmatrelvir/ritonavirDiscontinue use of bosentan at 
least 36 hours prior to initiation 
of nirmatrelvir/ritonavir. 
Refer to the bosentan product 
label for further information.
Hepatitis C direct 
acting antiviralselbasvir/grazoprevir,
glecaprevir/pibrentasvir↑ antiviral Increased grazoprevir 
concentrations can result in 
ALT elevations.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 111Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
ombitasvir/paritaprevir/ritona
vir and dasabuvir
sofosbuvir/velpatasvir/voxila
previrAvoid concomitant use of  
glecaprevir/pibrentasvir with 
nirmatrelvir/ritonavir. 
Refer to the 
ombitasvir/paritaprevir/ritonavi
r and dasabuvir label for 
further information.
Refer to the 
sofosbuvir/velpatasvir/voxilapr
evir product label for further 
information.
Patients on ritonavir -containing 
HCV regimens should continue 
their treatment as indicated. 
Monitor for increased 
nirmatrelvir/ritonavir or HCV 
drug adverse events with 
concomitant use.
HMG- CoA 
reductase 
inhibitorsatorvastatin,
rosuvastatin↑ atorvastatin
↑ rosuvastatinConsider temporary 
discontinuation of atorvastatin 
and rosuvastatin during 
treatment with 
nirmatrelvir/ritonavir. 
Atorvastatin and rosuvastatin 
do not need to be held prior to 
or after completing 
nirmatrelvir/ritonavir.
Hormonal 
contraceptiveethinyl estradiol ↓ ethinyl estradiol An additional, non -horm onal 
method of contraception should 
be considered during the 5 days 
of nirmatrelvir/ritonavir 
treatment and until one 
menstrual cycle after stopping 
nirmatrelvir/ritonavir .
Immunosuppressa
ntscalcineurin inhibitors:
cyclosporine,
tacrolimus↑ cyclosporine
↑ tacrolimusAvoid concomitant use of 
calcineurin inhibitors with 
nirmatrelvir/ritonavir when 
close monitoring of 
immunosuppressant 
concentrations is not feasible. 
If co-administered, dose 
adjustment of the 
immunosuppressant and close 
and regular monitoring for 
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 112Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
mTOR inhibitors:
everolimus,
sirolimus↑ everolimus 
↑ sirolimusimmunos uppressant 
concentrations and adverse 
reactions are recommended 
during and after treatment with 
nirmatrelvir/ritonavir. Obtain 
expert consultation to 
appropriately manage the 
complexity of this 
coadministration..
Avoid concomitant use of 
everolinus and si rolimus and 
nirmatrelvir/ritonavir.
Refer to individual 
immunosuppressant product 
prescribing information and 
latest guidelines for further 
information.
Janus kinase 
(JAK) inhibitorstofacitinib 
upadacitinib↑ tofacitinib
↑ upadacitinibDosage adjustment of 
tofacitinib is recommended. 
Refer to the tofacitinib product 
label for more information.
Dosage recommendations for 
co-administration of 
upadacitinib with 
nirmatrelvir/ritonavir depends 
on the upadacitinib indication. 
Refer to the upadacitin ib 
product label for more 
information.
Long -acting 
beta-adrenoceptor 
agonistsalmeterol ↑ salmeterol Avoid concomitant use with 
nirmatrelvir/ritonavir. The 
combination may result in 
increased risk of cardiovascular 
adverse events associated with 
salmeter ol, including QT 
prolongation, palpitations, and 
sinus tachycardia. 
Migraine 
medicationsrimegepant ↑ rimegepant Avoid concomitant use with  
nirmatrelvir/ritonavir.
Muscarinic 
receptor 
antagonistsdarifenacin ↑ darifenacin The darifenacin daily dose 
should not exceed 7.5 mg when 
co-administered with 
nirmatrelvir/ritonavir. Refer to 
the darifenacin product label 
for more information.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 113Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Narcotic 
analgesicsfentanyl,
hydrocodone, 
oxycodone,
meperidine
methadone↑ fentanyl
↑ hydrocodone
↑ oxycodone
↑ meperidine
↓ methadoneCareful monitoring of 
therapeutic and adverse effects 
(including potentially fatal 
respiratory depression) is 
recommended when fentanyl, 
hydrocodone, oxycodone, or 
meperidine is concomitantly 
administered with 
nirmatrelvir/ritonavir. If 
concomitant use wit h 
nirmatrelvir/ritonavir is 
necessary, consider a dosage 
reduction of the narcotic 
analgesic and monitor patients 
closely at frequent intervals. 
Refer to the individual product 
label for more information. 
Monitor methadone- maintained 
patients closely for evidence of 
withdrawal effects and adjust 
the methadone dose 
accordingly.
Neuropsychiatric 
agentssuvorexant
aripiprazole,
brexpiprazole,
cariprazine,
iloperidone,
lumateperone,
pimavanserin↑ suvorexant
↑ aripiprazole,
↑ brexpiprazole,
↑ cariprazine,
↑ iloperidone,
↑ lumateperone,
↑ pimavanserinAvoid concomitant use of 
suvorexant with  
nirmatrelvir/ritonavir.
Dosage adjustment of 
aripiprazole, brexpiprazole, 
cariprazine, iloperidone, 
lumateperone, and 
pimavanserin is recommended. 
Refer t o individual product 
label for more information.
Pulmonary 
hypertension 
agents (PDE5 
inhibitors)
Pulmonary 
hypertension 
agents (sGC 
stimulators)tadalafil (Adcirca®)
riociguat↑ tadalafil
↑ riociguatAvoid concomitant use with  
nirmatrelvir/ritonavir.
Dosage adjustment is 
recommended for riociguat. 
Refer to the riociguat product 
label for more information.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 114Table 4. Established and Other Potentially Significant Drug Interactions 
Drug Class Drugs within Class Effect on 
ConcentrationClinical Comments
Erectile 
dysfunction agents 
(PDE5 inhibitors)avanafil
sildenafil,
tadalafil,
vardenafil↑ avanafil,
↑ sildenafil,
↑ tadalafil,
↑ vardenafilDo not use 
nirmatrelvir/ritonavir with 
avanafil because a safe and 
effective avanafil dosage 
regimen has not been 
established.  
Dosage adjustment is 
recommended for use of 
sildenafil, tadalafil, or 
vardenafil with 
nirmatrelvir/ritonavir.  Refer to 
individual product labels for 
more information.
Sedative/hypnotics buspirone,
clorazepate,
diazepam,
estazolam,
flurazepam,
zolpidem
midazolam (administered 
parenterally)↑sedative/hypnotic
↑ midazolamA dose decrease may be 
needed for these drugs when 
co-administered with 
nirmatrelvir/ritonavir and 
monitoring adverse events
Co-administration of 
midazolam (parenteral) should 
be done in a setting which 
ensures close clinical 
monitoring and appropriate 
medical management in case of 
respiratory depression and/or 
prolonged sedation. Dosage 
reduction for midazolam 
should be considered, 
especially if more than a single 
dose of midazolam is 
administered. 
Refer to the midazolam 
product label for further 
information.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 11510.9. Appendix 9: Country- Specific Requirements
10.9.1. France
Contrat Unique
1.GCP Training 
Before enrolling an y participants, the investigator and an y subinvestigators will 
complete the Pfizer -provided Good Clinical Practice training course (“Pfizer GCP 
Training”) or training deemed equivalent by  Pfizer. Any  investigators who later join 
the study  will do the same before performing study -related duties. For studies of 
applicable duration, the investigator and subinvestigators will complete Pfizer GCP 
Training or equi valent every  3 years during the term of the study, or more often if 
there are significant changes to the ICH GCP guidelines or course materials. 
2.Study  Intervention 
No participants or third -party  payers will be charged for study  intervention.
3.Urgent Safet y Measures 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y 
measures taken b y the investigator to protect the study  participants against any  
immediate hazard, and of any  serious breaches of this protocol or of ICH GCP that
the investigator becomes aware of.
4.Termination Rights 
Pfizer retains the right to discontinue development of nirmatrelvir/ritonavir at an y 
time.
10.9.2. Germany
Local HIV testing at screening will be performed for participants in Germany  as required by  
the German HA (See Appendix 2).
Protocol Inclusion Criterion
1and associated Section 10.10.1 (Age and Sex) indicate: 
Inclusion Criterion 1: Participants aged 12 years or older and weighing ≥40 kg at screening: 
Participants aged 12 years or older at the time of signing the informed consent. 
Adolescent participants below the age of 18 years (or country
-specific age of 
majority) will only be enrolled if approved by the country regulatory/health authority. 
If these approvals have not been granted, only participants 18 years of age (or 
country -specific age of majority) or older at the time of signing of informed consent 
may be enrolled. 
Consistent with the EU conditional marketing authorization of nirmatrelvir/ritonavir, in 
German y, onl y adult participants ( ≥18 y ears) will be enrolled in the study .
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 11610.10. Appendix 10: Eligibility Criteria
10.10.1. Age and Sex
Inclusion Criterion 1: Participants aged 12 years or older and weighing ≥40 kg at screening:
Participants aged 12 years or older at the time of signing the informed consent. 
Adolescent participants below the age o f 18 years (or country
-specific age of 
majority ) will onl y be enrolled if approved b y the country  regulatory /health authority . 
If these approvals have not been granted, onl y participants 18 y ears of age (or 
country -specific age of majority ) or older at the time of signing of informed consent 
may be enrolled.
Refer to Appendix 4 for reproductive criteria for female (Section 10.4.1) participants.
10.10.2. Rebound of COVID
-19 Signs/Symptoms
Inclusion Criterion 2: Participants must have written docum entation, such as electronic health 
record, medical record, or prescription receipt of treatment with nirmatrelvir/ritonavir (verbal 
assertion of treatment is not acceptable) with patient
-reported 100% compliance (ie, 
completed a 5 day  course of nirmatrelv ir/ritonavir) . They  must have s ymptom alleviation or 
resolution in COVI D-19 signs/sy mptoms followed by  a worsening (rebound) of 
signs/sy mptoms after completing an initial 5 -day course of nirmatrelvir/ritonavir based on 
the judgement of both the participant and investigator.
10.10.3. SARS -CoV -2 Infection
Inclusion Criterion 5: SARS -CoV -2 infection as determined b y rapid antigen testing in an y 
specimen 
collected within 24 hours prior to randomization and collected within 2 weeks 
(14days) after the completion of the initial 5 -day treatment course of nirmatrelvir/ritonavir.
Note: If rapid antigen testing is performed at screening and baseline, the baselin e result will 
determine eligibility .
10.10.4. Risk of Developing Severe Illness from COVID -19
Inclusion Criterion 6: Has at least 1 characteristic or und erlying medical condition associated 
with an increased risk of developing severe illness from COVID -19 including:
Age ≥60 y ears;
BMI ≥25 kg/m2(or ≥85thpercentile for pediatric participants)
;
Current smoker (cigarette smoking within the past 30 day s) and history  of at least 
100lifetime cigarettes;
Chronic lung disease (if asthma requires daily  prescribed therapy );
Diagnosis of h ypertension;
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 117CVD, defined as history  of any  of the following: my ocardial infarction, TIA, stroke, 
HF, angina with prescribed nitr ate, CABG, PCI , carotid endarterectomy , aortic 
bypass, peripheral arterial disease;
Congenital heart disease;
Type 1 or Ty pe 2 diabetes mellitus;
CKD provided the participant does not meet exclusion criterion #5;
Chronic liver disease (provided the partici pant does not meet exclusion criterion #2); 
Sickle cell disease or thalassemia;
Dementia, neurodevelopmental disorders (eg, cerebral pals y, Down s yndrome) or 
other conditions that confer medical complexity  (eg, genetic or metabolic sy ndromes 
and severe congenital anomalies);
Active cancer, other than localized skin cancer, provided that the subject does not 
meet the exclusion criterion for being immunocompromised ( Section 5.2, Exclusion 
Criterion
7);
Medical -
related technological dependence (eg, CPAP [not related to COVID -19]).
Exclusion Criterion 6: Ox ygen saturation of <92% on room air obtained at rest within 
24hours prior to randomization. 
Note: for a potential participant who regularl y receives chronic supplementary ox ygen for an 
underly ing lung condition, oxy gen saturation should be measured while on their standard 
home ox ygen supplementation.
10.10.5. Prior/Concomitant Therapy
Exclusion Criterion 9: Current use of an y prohibited concomitant medication(s).
Current an y medications that are highl y dependent on CYP3A4 for clearance and 
which are contraindicated in combination with nirmatrelvir/ritonavir (see 
Appendix 8). Coadministration of nirmatrelvir/ritonavir with other medications that 
are not contraindicated but are highly  dependent on CYP3A4 for clearance may  
require dose adjustment or additional monitoring (See Appendix 8 in protocol).
Use of an y medications or substances that are strong inducers of CYP3A4 and that 
are contraindicated in combination with nirmatrelvir/ritonavir without the appropriate 
washout prior to the first dose of nirmatrelvir/ritonavir (se e Appendix 8 in protocol). 
The appropriate washout period for CYP3A4 inducers should be determined based on 
the prescribing information for the concomitant medication and in consultation with 
the medical monitor.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 11810.10.6. Other Treatments for COVID-19
Exclusion Criterion 11: Receiving other COVID -19 specific treatments within 30 day s of 
randomization a nd through Day  34, including but not limited to COVID
-19 antivirals 
(excluding a single 5 -day treatment course of nirmatrelvir/ritonavir that qualifies a 
participant for eligibility ), monoclonal antibodies for COVID -19.
10.10.7. Immunocompromised Criteria Details
Exclusion Criterion 7: Immunocompromised with ≥1 of the following:
1.Solid organ (eg, liver, heart, lung or kidney ) transplant recipient who is receiving 
immunosuppressive therapy
;
2.Receipt of CAR -T cell therap y or HCT either within 2 y ears of transplantation or who 
are receiving immunosuppressive therap y;
3.Moderate or severe primary  immunodeficiency  (eg, DiGeorge s yndrome, Wiskott 
Aldrich sy ndrome);
4. Use of at least 1 of the following immune- weakening medications:
a.Has received corticosteroids equivalent to prednisone ≥20 mg dail y for at least 
14 consecutive day s within 30 day s prior to study  entry .
b. Active treatment causing significant immunosu ppression, including alk ylating 
agents, antimetabolites, transplant -related immunosuppressive drugs, cancer 
chemotherapeutic agents, TNF blockers, or other highl y immunosuppressive 
drugs (eg, ustekinumab, anti CD20).
5.Active immunosuppressive treatment for solid tumor;
6.Hematological malignancy  (including leukemia, ly mphoma, and m yeloma);
7. Advanced or untreated HIV infection defined as CD4 cell counts <200/mm3, history  
of an AIDS -defining illness without immune reconstitution, or clinical manifestations 
of symptomatic HIV.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 11910.11. Appendix 11: Participant-Reported COVID-19- Related Signs and Symptoms
Sign and Symptom Collection [33] Eligibility Criterion #5 
Targeted (used for study 
entry)Signs and Symptom  
Collection
Cough X X
Shortness of breath or difficulty breathing X X
Fever (documented temperature >38 ˚C 
[100.4 ˚F]) or subjective fever (eg, feeling 
feverish)X
Feeling feverish X
Chills or shivering X X
Fatigue (low energy or tiredness) X X
Muscle or body aches X X
Diarrhea (loose or w atery stools) X X
Nausea (feeling like you wanted to throw  up) X X
Vom iting (throw  up) X X
Headache X X
Sore throat X X
Stuffy or runny nose X X
Loss of smell X X
Loss of taste X X
  
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 12010.12. Appendix 12: Protocol Amendment History
Amendment 1 (16 September 2022)
Overall Rationale for the Amendment: Modifications to the estimands, primary  anal ysis 
population, as well as a change in one of the secondary  endpoints which resulted in 
additional procedures necessitated t his amendment. Also included in this amendment are 
updated DDI tables, removal of RT- PCR testing as an option to determine eligibility , 
addition of a tertiary  endpoint, corrections, and general editorial changes to correct 
grammatical errors, to maintain c onsistency , and/or to increase clarity
Section # and Name Description of Change Brief Rationale Substantial or 
Nonsubstantial .
1.1 Synopsis, 3. 
OBJECTIVES, 
ENDPOINTS AND 
ESTIMANDS, 9.1.1.1 
Primary Estimand, 
9.1.1.2 Secondary 
Estimand, 9.2 Analysis 
Set and 9.3.2. Primary 
Endpoint(s)/Estimand(s) 
Analysis 2 The population in the estimands and 
the primary analysis population was 
upda ted with the requirement of a 
positive rapid antigen test at baseline to 
align with the inclusion/exclusion 
criteria.More inclusive and 
generalizable.Substantial
1.1 Synopsis, 3. 
OBJECTIVES, 
ENDPOINTS AND 
ESTIMANDS, 9.1.1.2 
Secondary Estimands 
and 9.1.2 Multiplicity 
AdjustmentEndpoint of: ‘Proportion of 
participants with SARS -CoV -2 RNA 
in NP swabs below the LLOQ (defined 
as <2.0 log 10copies/mL) on both Days 
5 and 10’. Removed as a secondary 
endpoint and added as a 
tertiary/exploratory endpoint.Replace d with a new 
secondary endpointSubstantial
1.1 Synopsis, 3. 
OBJECTIVES, 
ENDPOINTS AND 
ESTIMANDS, 9.1.1.2 
Secondary Estimands, 
9.1.2 Multiplicity 
Adjustment and 9.3.3 
Secondary EndpointsNew secondary endpoint/estimand of: 
‘Time to 2 consecutive negative rapid 
antigen test results.’ Added. The 
corresponding analysis for secondary 
endpoints were updated /added with 
more details.Based on regulatory 
feedbackSubstantial
1.1 Synopsis and 9.5 
Sample Size 
DeterminationUpdated sample size assumptions and 
the c orresponding calculation to reflect 
the change in the primary analysis 
population.To align with the changes in 
primary analysis population 
and eligibility criteria.Substantial
1.3. Schedule of 
Activities, 8.7.3. Rapid 
Antigen Assessments, 
and 10.10.3 SA R-CoV -
2 InfectionAmended to add self -administered 
daily rapid antigen tests for all study 
days between scheduled visits until 2 
consecutive negative rapid antigen test 
results are obtained at which point, 
rapid antigen testing will be performed 
only at re maining scheduled visits.Necessary to support new 
secondary endpointSubstantial
10.8 Appendix 8: 
Prohibited Concomitant 
Medications That May 
Result in DDIText describing Tables 4 and 5 was 
revised to clarify DDI table content. 
Tables were updated with information 
from the Fact Sheet for Healthcare 
Providers: Emergency Use 
Authorization for Paxlovid (August 
2022).Updates to the list of 
precautionary and prohibited 
medications.Substantial
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 121Section # and Name Description of Change Brief Rationale Substantial or 
Nonsubstantial .
3. OBJECTIVES, 
ENDPOINTS AND 
ESTIMANDSNew tertiary endpoint of: ‘Time (days) 
to sustained resolution of all targeted 
signs and symptoms through Day 28 
where sustained resolution is defined 
as the first of two consecutive days 
when all targeted COVID -19 
symptoms are scored as absent. ‘ addedBased on regulatory 
feedbac k,Nonsubstantial
1.3 Schedule of 
Activities, Section 8.7.1 
Viral RNA Assessment 
(NP Swab) and 8.7.3 
Rapid Antigen 
AssessmentsClarified in Section 8.7.1 that NP swab 
collection must occur prior to rapid 
antigen assessment, and clarified in 
SoA notes and Section 8.7.3 that rapid 
antigen testing must occur after NP 
swab collection.To ensure that assessments 
for the primary endpoint are 
prioritized.Nonsubstantial
4.2 Scientific Rational 
for Study Design and 
6.9 Prior and 
Concomitant TherapyDescribed rito navir as an inhibitor of 
CYP3A4 and provided guidance 
accordingly.To provide clinical guidance 
for participants who take 
concomitant medications 
metabolized by CYP3A4.Nonsubstantial
5.1 Inclusion Criteria 
and 10.10.3 and 
throughout the protocolRemoval of ‘confirmed’ in relation to 
SARS -CoV -2 infection‘Confirmed’ is generally 
used in association with RT -
PCR testing which has been 
removed from the protocol Nonsubstantial
6.1.1 Administration Updated timing of dose administration. To align with dosing 
administration in other C467 
protocols.Nonsubstantial
8.1. Administrative and 
Baseline ProceduresThe total blood sampling volume 
reduced to approximately 160 mL.More refined estimate of 
total blood volume received 
from central laboratory for 
the study.Nonsubstantial
8.1.1.2 Secondary 
ContactsAdded that secondary contacts may be 
used to determine if a participant is lost 
to follow -up or vital status check.To clarify utility of 
collecting secondary contact 
information.Nonsubstantial
8.7.6.1. Plasma for 
Protein AnalysisBlood sample volume reduced to 6 mL. More refined estimate of 
blood volume received from 
central laboratory for the 
study.Nonsubstantial
10.1.5 Data Monitoring 
CommitteeIncluding E -DMC monitoring of 
baseline SARS -CoV -2 RNA levels.To ensure population is 
consistent with study design 
assumptions.Nonsubstantial
10.2 Appendix 2: 
Clinical Laboratory 
TestsClarified that FSH testing if needed is 
to be performed locally.Correction Nonsubstantial
10.10.4. Risk of 
Developing Severe 
Illness from COVID -19Added Age ≥60 years. Correction Nonsubstantial
10.4.1 Female 
Participant 
Reproductive Inclusion 
CriteriaText updated for consistency with 
other C467 studies.Updated to align with other 
C467 protocolsNonsubstantial
Throughout the protocol Remove RT -PCR To simplify eligibility 
assessment, SARS -CoV -2 
infection will be confirmed 
by rapid antigen test onlyNonsubstantial
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 122Section # and Name Description of Change Brief Rationale Substantial or 
Nonsubstantial .
Throughout the protocol General editorial changes. To correct grammatical 
errors, to maintain 
consistency, and/or to 
increase clarity.Nonsubstantial
Amendment 2 (01 February 2023)
Overall Rationale for the Amendment: The German HA has requested for all participants 
to be enrolled in Germany  to undergo HIV testing at screening. Participants who do not 
consent to the screening HIV test will not be able to participate in the study. I n addition, 
consistent with the EU con ditional marketing authorization of nirmatrelvir/ritonavir, this 
amendment clarifies that in German y, onl y adult participants ( ≥18 y ears) will be enrolled in 
the study .
Section # and Name Description of Change Brief Rationale Substantial or 
Nonsubstantial .
SoA, Table 2, Section 
10.9.2 Country 
Specific 
RequirementsHIV diagnostics at screening added to 
the laboratory assessments for 
participants in Germany.As above. Nonsubstantial
Title page Added Clinicaltrials.gov ID The ID became available at 
the time of the protocol 
amendment.Nonsubstantial
Multiple sections 
throughoutMinor text updates to clarify protocol 
text and correct minor errors and typos 
from previous versions.To clarify protocol text and 
correct inadvertent errors.Nonsubstantial
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 123Amendment 3 (12 May 2023)
Overall Rationale for the Amendment: The protocol was primaril y amended to update the primary anal ysis population. Additional 
revisions are noted in the table below. 
Description of Change Brief Rationale Section # and Name
Substantial Modification(s)
Primary and secondary estimands and the 
mITT analysis set description have been 
updated to include that participants must 
have a positive viral RNA NP swab test 
result at baseline.The study primary endpoint is based on change in viral SARS -CoV -2 
RNA level measured in NP swabs from Baseline to Day 5, therefore a 
quantifiable viral RNA NP swab test result at baseline is necessary to 
enable assessment of the primary endpoint.Section 1.1 Synopsis
Section 3 Objectives, Endpoints, a nd Estimands
Section 9.1.1.1 Primary Estimand
Section 9.1.1.2 Secondary Estimands
Section 9.2 Analysis Sets
Sample size calculation updated. To align with the update for primary analysis population. Section 9.5 Sample Size Determination
Non-substantial Modification(s)
Update to text regarding viral RNA 
assessments (NP swab) and rapid antigen 
assessments. To align with changes introduced with Protocol Amendment 01 
(16Sep 2022) because as noted in the Summary of Changes table 
within Protocol Amendment 0 1, SARS -CoV -2 infection is required to 
be confirmed by rapid antigen test only (PACL dated 03 Oct 2022).
To clarify that the Screening and Baseline (Day 1) visits are exempt 
from the protocol -directed sequencing of NP and RAT (PACL dated 
01Nov 2022).Section 1.3 Schedule of Activities
Section 8.7.1 Viral RNA Assessment (NP Swab)
Section 8.7.3 Rapid Antigen Assessments
Update to inform that the EMA has 
granted marketing authorization approval 
for nirmatrelvir/ritonavir.To update the regulatory status of nirmatrelvir/ritonavir in the EU. Section 2.3.2 Benefit Assessment
Minor editorial updates including link to 
Table 3 in Appendix 8. For clarification and to guide the reviewer to the correct Table in 
Appendix 8. Section 6.9 Prior and Concomitant Ther apy
Minor editorial updates. To correct grammatical errors, to maintain consistency, and/or to 
increase clarity, and align with the most current protocol template 
(14Apr 2023).Throughout the protocol, including:
Section 10.1.3.2 Informed Assent Process
Section 10.1.4 Data Protection
Section 10.1.6 Dissemination of Clinical Study Data
Section 10.1.7 Data Quality Assurance
Section 10.1.9 Study and Site Start and Closure
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 124Description of Change Brief Rationale Section # and Name
Section 10.1.10 Publication Policy
Updated text on the contraception 
requirements during the 5 days of 
nirmatrelvir/ritonavir treatment.Updated to align with the latest version of the USPI (dated 
18Apr2023)Section 10.4.3 Contraception Methods
Updated section header. Updates to 
Table 3 (Drugs That are Contraindicated 
With Nirmatrelv ir/Ritonavir) and Table 4 
(Established and Other Potentially 
Significant Drug Interactions)Updated to align with the latest version of the USPI (dated 
18Apr2023)Section 10.8 Appendix 8
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 12510.13. Appendix 13: Abbreviations
The following is a li st of abbreviations that may  be used in the protocol. 
Abbreviation Term
Abs absolute
AE adverse event
AKI acute kidney  injury
ALT alanine aminotransferase
AST aspartate aminotransferase
AxMP auxiliary  medicinal product
b-hCG b-human chorionic gonadotropin
BP blood pressure
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI chronic kidney  disease epidemiology  
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CSR Clinical Study  Report
CT computed tomograph y/clinical trial
CTIS Clinical Trial I nformation Sy stem
CYP cytochrome P450
DCT data collection tool
DDI drug-drug interaction 
DILI drug-induced liver injury
DU dispensable unit
EC ethics committee
ECC emergency  contact card
ECG electrocardiogram or electrocardiography
eCrCl estimated creatinine clearance
eCRF electronic case report form
EDB exposure during breastfeeding
E-DMC External Data Monitoring Committee
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
EGFR epidermal growth factor receptor
EMA European Medicines Agency
EOT end of treatment
EPIC-HR Evaluation of Protease Inhibition for COVI D-19 in High- Risk 
Patients
eSAE electronic serious adverse event
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 126Abbreviation Term
ESR erythrocy te sedimentation rate
EU European Union
EudraCT European Union Drug Regulating Authorities Clinical Trials 
(European Clinical Trials Database)
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
HA health authority
HCP health care professional
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency  virus
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD Informed Consent Document
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
ID identification
IMP investigational medicinal product
IND Investigational New Drug
INR international normalized ratio
IPAL Investigational Product Accountability  Log
IPM investigational product manual
IRB Institutional Review Board
IRT Interactive Response Technology
JAK Janus Kinase
KDIGO Kidney  Disease: I mproving Global Outcomes
LFT liver function test
LLOQ lower limit of quantitation
LTFU long-term follow up
mITT modified intent -to-treat
MMRM mixed model repeated measures approach
MQI medically  qualified individual
NA not applicable
NCT National Clinical Trial
NIMP noninvestigational medicinal product
NOAEL no observed adverse effect level
NP nasophary ngeal
OP orophary ngeal
PACL protocol administrative change letter
PDE5 phosphodiesterase -5
P-gp p-glycoprotein
PK pharmacokinetic(s)
PR pulse rate
PSSA Pfizer’s Serious Adverse Event Submission Assistant
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 127Abbreviation Term
PT prothrombin time
QTL quality  tolerance limit
RAT rapid antigen test
RBC red blood cell
RNA ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
SAE serious adverse event
SAP Statistical Analy sis Plan
SARS -CoV -2 severe acute respiratory  syndrome coronavirus 2
SC subcutaneous(l y)
Scr serum creatinine
Scys serum cy statin C
sGC soluble guan ylate cy clase
SoA schedule of activities
SOP standard operating procedure
SRSD Single Reference Safety Document
SUSAR Suspected Unexpected Serious Adverse Reaction
T telemedicine
T bili total bilirubin
TCID50 Median Tissue Culture Infectious Dose
ULN upper limit of normal
US United States
USPI United States Prescribing I nformation
WBC white blood cell
WOCBP woman/women of childbearing potential
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 12811.REFERENCES
1. Carlin AF, Clark AE, Chaillon A, et al. Virologic and I mmunologic Characterization 
of COVID -19Recrudescence after Nirmatrelvir/Ritonavir Treatment. Preprint: 18 
May 2022. Clin Infect Dis. 2022;10.1093/cid/ciac496.
2. Gupta K. SJ, Stack G., et al. Rapid Relapse of S ymptomatic SARS -CoV -2 Infection 
Following Earl y Suppression with Nirmatrelvir/Ritona vir. Preprint 26 Apr 2022. 
Report Number: v1. 2022. Available from: https://doi.org/10.21203/rs.3.rs -
1588371/v1.
3. Charness M. GK, Stack G., Stry mish J., Adams E., L indy D., Mohri H., and Ho D. 
Rapid Relapse of Sy mptomatic Omicron SARS -CoV -2 Infection Fol lowing Earl y 
Suppression with Nirmatrelvir/Ritonavir. 2022. Available from: 
https://www.researchsquare.com/article/rs -1588371/v3.
4. Julie Boucau RU, Caitlin Marino, James Regan, James P. Fl ynn, Manish C. 
Choudhary , Geoffrey  Chen, Ashley  M. Stuckwisch, Jos h Mathews, May  Y. L iew, 
Arshdeep Singh, Zahra Rey nolds, Surabhi L. Iyer, Grace C. Chamberlin, Tammy  D. 
Vyas, Jatin M. Vy as, Sarah E. Turbett, Jonathan Z. L i, Jacob E. Lemieux, Amy  K. 
Barczak, Mark J. Siedner. Virologic characterization of sy mptom rebound f ollowing 
nirmatrelvir -ritonavir treatment for COVID- 19. medRxiv. 2022.
5. Ranganath N, O'Horo JC, Challener DW, et al. Rebound Phenomenon after 
Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease -2019 in High- Risk Persons. 
Clin I nfect Dis. 2022;10.1093/cid/ciac481.
6. US Food and Drug Administration. Guidance for assessing COVID -19-related 
symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and 
biological products for COVID. 2020. Available from: 
https://www.fda.gov/regulato ry-information/search -fda-guidance -
documents/assessing -covid -
19-related -symptoms -outpatient -adult -and-adolescent -
subjects -clinical -trials
-drugs. Accessed: 29 June 2021.
7. John Hopkins University . COVID -19 Dashboard by  the Center for S ystems Science 
and Engineering (CSSE) at Johns Hopkins University  (JHU). Available from: 
https://coronavirus.jhu.edu/map.html. Accessed on: Jun 2020.
8. US Food and Drug Administration. COVI D-19 Vaccines. Available from: 
https://www.fda.gov/emergency -preparedness- and-response/ coronavirus- disease -
2019- covid -19/covid-19- vaccines. Accessed on: 29 Jun 2021.
9. US Food and Drug Administration. Fact sheet for healthcare providers emergency  use 
authorization of PaxlovidTM. Available from: 
https://www.fda.gov/media/155050/download. Accessed: 27 July  2022.
10. US Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency  
Use Authorization for Molnupiravir. February  2022. Available from: 
https://www.fda.gov/media/155054/download. Accessed: 22 February  2022.
11. Veklur y® (Remdesivir) Significantl y Reduced Risk of Hospitalization in High -Risk 
Patients with COVI D-19 Available at: https://www.gilead.com/news- and-press/press -
room/press -releases/2021/9/veklury -remdesivir -significantly -reduced-risk- of-
hospitalization -in-highr isk-patients- with-covid19 [press release]. 22 Sep 2021.
12. Pfizer. I nvestigator's Brochure PF-07321332. Data on file.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 12913. European Medicines Agency . Paxlovid (PF -07321332/ritonavir). Available from: 
https://www.ema.europa.eu/en/documents/overview/paxlovid -epar-medicine -
overview_en.pdf. Accessed: 27 Apr 2023.
14. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS -CoV -2 in 
an immunocompromised patient. J I nfect Chemother. 2021;27(2):387-89.
15. Baang JH, Smith C, Mirabelli C, et al. Prol onged Severe Acute Respiratory 
Syndrome Coronavirus 2 Replication in an I mmunocompromised Patient. J Infect 
Dis. 2021;223(1):23-27.
16. Administration UFD. (2022). Fact Sheet For Patients, Parents, and Caregivers. 
Emergency  Use Authorization (EUA) of PAXLO VID For Coronavirus Disease 2019 
(COVID -19). Available from: https://www.fda.gov/media/155051/download. 
Accessed on: March 3.
17. Food and Drug Administration Guidance for Industry : FDA Guidance for Assessing 
COVID -19-Related Sy mptoms in Outpatient Adult a nd Adolescent Subjects in 
Clinical Trials of Drugs and Biological Products for COVID -19 Prevention or 
Treatment. [Internet]. 2020. Available from: https://www.fda.gov/regulatory -
information/search -fda-guidance -documents/assessing -covid -
19-related- symptoms -
outpatient -adult -and-adolescent -subjects
-clinical -trials -drugs.
18. Ware J KM, Bjorner J, et al. Development User's Manual for the SF- 36v2® Health 
Survey . Quality Metric Incorporated; 2007.
19. US Bureau of Labor Statistics. Effects of COVID -19 Pandemic on Productivity  and 
Costs Statistics. Available from: https://www.bls.gov/covid19/effects -of-covid -19-
pandemic -
on-productivity -and-costs -statistics.htm. Accessed on: 08 Jun 2021.
20. Reilly  MC, Zbrozek AS, Dukes EM. The validit y and reproducibility  of a work 
productivity  and activity  impairment instrument. Pharmacoeconomics. 
1993;4(5):353 -
65.
21. Rabin R, Gudex C, Selai C, et al. From translation to version management: a history  
and review of methods for the cultural adaptation of the EuroQol five -dimensional 
questionnaire. Value Health. 2014;17(1):70 -6.
22. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ -5D- 5L: mapping 
the EQ -5D- 5L to EQ -5D- 3L value sets. Value Health. 2012;15(5):708 -15.
23. Ramos -Goni JM, Pinto -Prades J L, Oppe M, et al. Val uation and Modeling of EQ -5D-
5L Health States Using a Hy brid Approach. Med Care. 2017;55(7):e51- e58.
24. Yang Y, Brazier J, L ongworth L . EQ-5D in skin conditions: an assessment of validity  
and responsiveness. Eur J Health Econ. 2015;16(9):927-39.
25. Janss en MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ -5D- 5L 
compared to the EQ -5D- 3L across eight patient groups: a multi -country  study . Qual 
Life Res. 2013;22(7):1717-27.
26. Herdman M, Gudex C, Lloy d A, et al. Development and preliminary  testing of the 
new five -level version of EQ -5D (EQ -
5D-5L). Qual L ife Res. 2011;20(10):1727 -36.
27. Agborsangay a CB, Lahtinen M, Cooke T, et al. Comparing the EQ -5D 3L and 5L : 
measurement properties and association with chronic conditions and multimorbidity
in the general population. Health Qual Life Outcomes. 2014;12:74.
28. EuroQol G. EuroQol --a new facility  for the measurement of health- related quality  of 
life. Health Policy . 1990;16(3):199-208.
Nirm atrelvir/ritonavir
Protocol C4671042 
Final Protocol Amendment 4, 29 June 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
Page 13029. U.S. Department of Health and Human Services NIoH, Natio nal Heart, Lung, and 
Blood Institute. A Pocket Guide to Blood Pressure Measurement in Children. May  
2007. Available from: https://www.nhlbi.nih.gov/files/docs/bp_child_pocket.pdf. 
Accessed: 16 February  2022.
30. U.S. Department of Health and Human Services NIoH, National Institute of Allergy  
and Infectious Diseases, Division of AIDS,. Division of AIDS (DAIDS) Table for 
Grading the Severity  of Adult and Pediatric Adverse Events, Corrected Version 2.1. 
July 2017. Available from: 
https://rsc.niaid.nih.gov/site s/default/files/daidsgradingcorrectedv21.pdf. Accessed: 
10 Jun 2021.
31. Benjamini Y, & Hochberg, Y. Controlling the false discovery rate: a practical and 
powerful approach to multiple testing. . Journal of the Roy al Statistical Society . 
1995;57:289 –300.
32. Inker LA, Enean ya ND, Coresh J, et al. New Creatinine -and Cy statin C -Based 
Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737 -
49.
33. US Food and Drug Administration. Assessing COVID -19-Related Sy mptoms in 
Outpatient Adult and Adol escent Subjects in Clinical Trials of Drugs and Biological 
Products for COVID -19 Prevention or Treatment. 2020. Available from: 
https://www.fda.gov/regulatory -information/search -fda-guidance -
documents/assessing -covid -
19-related -symptoms -outpatient -adult -and-adolescent -
subjects -clinical -trials
-drugs. Accessed: 25 Mar 2021.
D o c u m e nt A p p r o v al R e c o r d 
D o c u m e nt N a m e: 
D o c u m e nt Titl e: 
Si g n e d B y: D at e( G M T) Si g ni n g C a p a cit y 
P P D 
P P D 